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The objective of this research is to further define the relationship between the charge state 
of insulin, and the self assembly properties of insulin and PEGylated insulin in solution.  
Polyethylene glycol (PEG) chains were covalently attached to insulin in order to evaluate 
their impact on insulin’s systemic duration of action after pulmonary dosing.  This thesis 
will focus on the assembly properties of the PEG-insulin and insulin, and also 
demonstrate how the charge state, which was modified by the covalent attachment of 
PEG, relates to different modes of behavior by anion and cation exchange 
chromatography. In addition, explain how modifying the assembly state extends to 
improving formulation properties of spray-dried insulin powders. 
This thesis is an investigation into the relationship of insulin’s charge state controlled by 
pH and how the charge state affects the self assembly of insulin, especially when the zinc 
ion is removed. Ionic interaction is one of the major forces affecting insulin assembly. 
The theory that a change in the charge state of insulin could modulate the ionic 
interaction and reduce hexamer formation at alkaline conditions was investigated. 
Experiments were designed to measure the level of hexamer with light scattering, and the 
amount of hexamer was then correlated with the pH and zinc content of the solutions. The 
importance of the charge state of the monomer and its behavior extends to 
chromatography and purification modes as well. Specifically, the purification of various 
species of PEGylated insulin presents a challenge.  By varying mobile phase pH which 
induces the charge to insulin, an ion exchange method demonstrated very high resolution 
and controllable interaction between the ion exchange media and the insulin derivatives. 
A highly accurate method for determining molecular weight and thus the average 
associated state of insulin in solution has been developed using the MALS (Multi-Angle 
Light Scattering).  Insulin concentration, pH, and metal ion concentrations, were in 
pharmaceutically relevant ranges.  The MALS method was developed to evaluate how the 
parameters above affect the self-assembly properties of insulin, and use the assembly 
properties to improve formulations of insulin or PEGylated insulin. To use the light 
scattering technique the dn/dc (change in refractive index with change in concentration) is 
required. During the method development, the dn/dc of insulin was measured at 690 nm, 
and a value of 0.185 mL/g based on theory was confirmed. 
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A novel approach for preparing insulin powders with improved chemical stability, based 
on maintaining the dissociation of hexamers in solution during the spray drying process 
was developed.  The mode presented here is to remove the zinc ions from solution, 
increase the pH from 6.6 to 7.8, and maintain a low concentration of insulin 
approximately 2 to 15 mg/mL.  Each of these factors alone decreases the hexamer 
population in solution, but by combining all three factors, hexamers are driven to very 
low levels of equilibrium. The increased stability of the powders is predominately related 
to the decrease in covalent insulin dimer (CID). The data presented correlates a reduced 
hexamer population in the solution with lower levels of CID’s in the dry powder 
compared to controls.  The CID formation rate was reduced by 40% compared to a 
control. 
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1 
INTRODUCTION
Insulin has been studied and used as a therapeutic agent for nearly 90 years.  It has 
continually been at the leading edge of biochemistry and technology development.  From 
amino acid sequencing, to ultra high purification of human insulin expressed from E. coli 
(Escherichia coli) bacteria, it has been used as a model of how biotechnology can 
improve everyone’s life.  
Insulin is susceptible to the deactivating physical aggregation phenomena that plague 
most proteins in solution, but because of its compact size and disulfide linkages it can be 
considered one of the more stable proteins. Insulin has 51 amino acids divided into 2 
chains (A and B), with 3 disulfide bonds.  USP molecular weight for human insulin is 
stated as 5807.58 Da.  Stability is further enhanced by insulin’s ability to self associate 
into dimers and hexamers, essentially driven by increased concentration.  Figure 1 shows 
the primary structure of human insulin (Brange et al. 1994).  
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Figure 1: Primary sequence of human insulin. The H = amino acids involved with 
hexamer formation. The D = amino acids involved with dimer formation. 
 
A fundamental precept for stabilizing insulin in solution has been to drive the equilibrium 
assembly state toward complete formation of hexamers.  6 insulin molecules form a donut 
shaped structure with 2 zinc ions in the center. The assembled hexamer is approximately 
5 nanometers in size.  This is important to the physical and chemical stability of the 
parenteral formulations because hexamers are resistant to fibrillation or inactivated 
aggregates (Brange et al. 1982, Brange et al. 1983a, Brange et al. 1983b, Brange et al. 
1983c, Brange et al. 1985, Brange et al. 1987a, Albisser et al. 1982, Katakam et al. 
1995).  Insulin hexamer formation is a complex interaction driven by multiple factors. 
The concentration of insulin itself is critical.  At neutral pH, and below 0.5 mg/mL of 
insulin, the hexamer has difficulty forming. The interaction of pH, ionic strength, zinc 
ions, insulin concentration, other auxiliary substances such as phenol, contribute to the 
equilibrium state of the hexamer population in solution (Berchtold et al. 1999, 
Brange 1994, Goldman et al. 1994).  To achieve hexamers, monomeric insulin first needs 
3 
to assemble to non-covalent dimers. The non-covalent dimer is a very stable structure in 
neutral insulin solutions, and does not require zinc to form.  It forms at very low 
concentrations (~1 μg/mL), and is stabilized by both hydrophobic interactions and 
hydrogen bonds.  The dominant interaction is the hydrophobic residues from the alpha 
helix of B9-B24 with the same helix from another monomer. The extended B21-B30 beta 
strands from each monomer form an anti-parallel beta sheet with 4 hydrogen bonds to 
stabilize the structure. Within that beta sheet the Lys B29 and Asp B28 are key amino 
acids for the manipulation of many of insulin’s properties. As concentration increases 
three non-covalent dimers assemble to form hexamers.  The A13-14, B1-2, B14, and 
B17-18, form a hydrophobic patch that interacts with each other from each dimer 
involved.  The hexamer can form without zinc, but stability is enhanced by 2 zinc ions 
associating with the six B-10 histidines in the center of the doughnut shaped hexamer. 
In 1936 insulin was first formulated using zinc, after discovering zinc is part of the insulin 
crystals in the pancreas (Howell et al. 1978).  The most common ratio of zinc for 
formulations is 2 moles of zinc II ion, to 6 moles of insulin. Zinc is one of several 
components that will stabilize the insulin hexamer in solution (Arakawa et al. 1982, 
Blackshear et al. 1983, Brange et al. 1986a, Brange et al. 1992a, Brange et al. 1992b, 
Brange et al. 1992c). In addition, at very high insulin concentrations the zinc stabilized 
hexamers will stack into long repeating units.  This repeating structure is the basis for the 
crystallization and purification of insulin for pure drug substance manufacturing (Brange 
et al. 1987b, Kadima et al. 1991).  Figure 2 is a schematic that illustrates the equilibrium 
of insulin assembly behavior and fibrillation. 
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Figure 2: Schematic of insulin assembly behavior. (Brange et al. 1994) 
 
For the design of each insulin product, prioritization of the dominant product parameter is 
chosen, for example, long acting insulin which is designed to have a PK and PD from 
12 to 24 hours (Brange 1967b, Kang et al. 1991).  This long action can be achieved 
formulation-wise by strongly promoting hexamer assembly. One such product example is 
Ultralente insulin.  This insulin product is formulated with approximately 20 extra zinc 
ions per hexamer in addition to the standard 2 zinc ions present with normal solutions of 
insulin hexamer.  The effect is to drive the equilibrium completely to hexamers that stack 
and form insoluble rhombohedral crystals at neutral pH. This crystalline suspension is 
injected into the subcutis and the crystals dissolve slowly as the concentration of all 
components are diluted by the bodily fluids (Hildebrandt et al. 1995, Kang et al. 1991, 
Kolendorf et al. 1978).  This releases the soluble insulin into the blood over the course of 
12-18 hours.  As with many physical phenomena an advantage gained is counteracted by 
certain disadvantages. The disadvantage for crystalline insulin is controlling particle size 
distribution during production; because large crystals dissolve too slowly and small 
crystals dissolve too quickly. Managing this complex interaction of insulin assembly to 
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maximize the product advantage and minimize its disadvantages is the goal of the protein 
scientist for each application required. 
This complexity allows formulators many parameters to manipulate, to achieve the 
desired effects.  Table 1 (provided by the FDA) is a summary of insulin products 
currently available to patients.  This list demonstrates the ability of scientists to extend 
and contract the action of insulin by combining the physico-chemical properties in the 
desired balance. Various products from the table will be discussed throughout the thesis 
to exemplify certain properties. 
Table 1: FDA Currently Approved Insulin Products (2008) 
Type of Insulin Examples Onset of Action Peak of Action Duration of Action
Humulin 50/50
Humulin 70/30
Humalog Mix 
75/25
Humalog Mix 
50/50
Eli Lilly
Novolin 70/30
Novolog Mix 70/30
Novo Nordisk
Levemir (detemir) 
Novo Nordisk 1 hour none 24 hours
Novolin L          
Novo Nordisk
Ultralente           
Eli Lilly
Lantus (glargine)   
Aventis
Long-acting
Intermediate- and short-
acting mixtures
The onset, peak, and duration of action of these mixtures would 
reflect a composite of the intermediate and short- or rapid-acting 
components, with one peak of action.
4-8 hours 8-12 hours 10-30 hours
1 hour none 24 hours
Intermediate-acting (NPH) 
1-3 hours 8 hours 20 hours
1-2.5 hours 7-15 hours 18-24 hours
Humulin N            
Eli Lilly
Humulin L            
Eli Lilly
Novolin N          
Novo Nordisk
Short-acting (Regular)
30-60 minutes 50-120 minutes 5-8 hours
Novolin R       
Novo Nordisk
Humulin R            
Eli Lilly
Rapid-acting
15 minutes 30-90 minutes 3-5 hours
15 minutes 40-50 minutes 3-5 hours
Humalog (lispro)    
Eli Lilly
NovoLog (aspart)   
Novo Nordisk
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In addition to formulation techniques for achieving PD and PK control, chemically 
modifying insulin by amino acid substitution or attachment of additional polymers and 
amino acids has become a very powerful approach.  Several modified insulin products 
have been FDA approved.  Eli Lilly’s Humalog (Lispro) approved in 1996, is a prime 
example of the success possible with the chemical modification approach.  By simply 
switching positions of the B28 and B29 amino acids of insulin, the noncovalent dimer 
stability is strongly disrupted (Bakaysa et al. 1996, Brems et al. 1992, Brange et al. 
1999).   The insulin product is categorized as fast-acting monomeric insulin. According to 
the data on package insert, after subcutaneous injection, Lispro reaches peak serum 
concentration in about 30 minutes compared to regular insulin’s peak concentration at 
50 minutes. Even though Lispro is monomeric after injection the formulation in the vial is 
stabilized to hexamer using zinc and phenol. A more current insulin analogue product 
which received FDA approval in 2005 is Novo Nordisk’s Levemir.  Levemir is 
long-acting insulin (Hashimoto et al. 1989, Havelund et al. 2004, Markusen et al. 1987, 
Vague et al. 2003, Ellmerer et al. 2003, Heinman et al. 1999). The package insert states 
peak serum concentration is reached in 6 to 8 hours with no pronounced peak and clears 
the system in about 24 hours. A C14 fatty acid chain is added to the B29 Lys amino acid 
and the final amino acid B30 Thr (DesB30) is deleted. This configuration allows the 
hexamers to stack with the fatty acids associating between the top and bottom doughnut 
shaped hexamers. Phenol and zinc are used to further promote the stability of the large 
assemblies, contributing to the long action after subcutaneous injection.  Additionally, the 
fatty acid has high binding affinity to a pocket on HSA (human serum albumin), and 98% 
of the Levemir is temporarily bound to HSA in the blood further prolonging the 
mechanism of action. 
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Modifying insulin to manipulate the physical and chemical properties continues to be a 
very active field of research and development (Brange J et al 1999, Brange et al. 1990). 
With the advent of protein PEGylation the number of insulin derivatives conceived is 
easily in the hundreds (Harris 1992, Delgado et al. 1992, Beauchamp et al. 1983).  PEG 
has gained interest for PEGylating many drugs to reduce immunogenicity and extend 
bioavailability (Abuchowski et al. 1977, Nucci et al. 1991, Salhanick et al. 2005, 
Tompkins et al. 1981, Uchio et al. 1999, Delgado et al. 1992, Davis et al. 1981). Given 
the success of insulin analogues PEGylation of insulin is an obvious area to investigate. 
PEGylation of insulin is being studied by several investigators to discover if covalent 
attachment of PEG (polyethylene glycol) can enhance any of the properties of insulin 
(Hinds et al. 2000a, Hinds et al. 2000b, Dou et al. 2007, Liu et al. 1997, Calcetti et al. 
1998, Calcetti et al. 1999, Calcetti et al. 2000, Calcetti et al. 2004, Ehrat et al. 1983, 
El-Sayed et al. 2001).   
Since the hexamer equilibrium is one of the main tools of formulation scientists, the 
association patterns and chemical behavior of various PEGylated insulin derivatives 
become fundamental properties to elucidate. The Phe B1 and the Lys B29 are the most 
popular sites for experimentation.  This is because the sites both have primary amines that 
are very reactive, and attaching a molecule is relatively easy.  B29 is directly involved 
with the noncovalent dimer interface, so it will immediately change the assembly 
behavior. B1 is involved with hexamer formation and can also affect assembly behavior. 
Both sites are charged and derivitization will reduce the isoelectric point of 5.3. Both sites 
are away from the region of the molecule that is involved with the human receptor 
binding, and have a small impact on bioavailability.  The A1 terminus is also easily 
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modified, however it is adjacent to the receptor binding site, and modifications to it 
should be avoided (Brange 1990). 
The structure of this thesis is not typical, and is modified to reflect the discussion of 
method development of several techniques in concert with the property of insulin being 
investigated.  Therefore an experimental section reappears in each chapter.  The 
schematic in Figure 3 shows how the research in this thesis evolved, and how each 
chapter is linked to the next. 
Figure 3: Schematic of thesis research. 
 
Chapter 1 aims to correlate the reduced rates of degradation of insulin in spray dried 
powders with reduced hexamer population (by increased pH and reduced zinc content) 
using an HPLC stability study. The data confirms the hypothesis  that the contact points 
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between noncovalent dimers in each hexamer assembly promote covalent dimer 
formation, and by reducing the hexamer population before spray drying, the final powder 
forms less covalent dimer. The RP-HPLC method used to track the degradation products 
of insulin is extensively described. The improved spray dried powder formulation 
technique will be outlined, including the technique for removing zinc. An outline of the 
MALS technique is discussed and the experiment for correlation of hexamer formation 
with zinc and pH is summarized. 
Chapter 2 aims to relate pH and charge state of insulin and PEG-insulin derivatives to 
rational optimization of ion exchange methods to ensure high purity of PEG derivatives. 
The difficulty of derivitizing insulin by PEGylation and acetylation on the primary 
amines is outlined.  The results show how pH can be used to achieve optimal separation 
by ion exchange. 
Chapter 3 aims to confirm the hypothesis that attached PEG interferes with dimer and 
hexamer assembly of PEG-insulin derivatives. The assembly state of the derivatives is 
evaluated with pH and zinc as variables. The method development of the MALS 
technique and measurement of the dn/dc parameter for insulin and PEG-insulin is 
discussed. The assembly state behavior is critical to evaluating formulation approaches. 
Chapter 4 summarizes the importance of zinc and pH on analytical and formulation 
techniques, and discusses the mechanisms of hexamer disassembly related to pH and 
derivitization especially when no zinc is present.  Areas for additional work are discussed. 
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1 SPRAY DRIED POWDERS WITH INCREASED STABILITY BY 
REDUCED ZINC CONTENT
1.1 Introduction 
For chemical stability of parenteral formulations of insulin, hexamers provide the 
foundation of rigid structure upon which further rigidity is supplied by the addition of 
excipients.  The reduction in conformational flexibility is a key to reducing most of the 
chemical degradation pathways of insulin. While rigidity is critical, the pH of the solution 
has a moderate effect on insulin degradation. Insulin degrades by a number of chemical 
reactions.  Degradation during storage of injectable insulin formulations can be classified 
in two main categories: hydrolysis and intermolecular transformation reactions leading to 
high molecular weight protein (HMWP) products (Strickley et al. 1996). 
The impact of pH on the degradation of insulin was studied extensively by Jens Brange in 
his book “Stability of Insulin” (1994). Hydrolytic degradation was highest in acidic pH, 
decreasing to a minimum at a pH of 6.5.  The predominant hydrolysis product at low pH 
was the A21 Asn deamidation product. Deamidation is the loss of an ammonia group.  At 
neutral pH hydrolysis flattens out.  At alkaline pH 7.5-9.0 hydrolysis increases again, but 
deamidation now occurs predominantly at B3 Asn. The A21 deamidation rate in the 
acidic pH range is faster than B3 deamidation rate in the alkaline range (Brange et al. 
1992f). The HMWP formation is high at acid pH with many formulations, but the rate is 
relatively flat in the pH range from 6.5 to 8.0.  An accelerated rate of formation of 
HMWP is observed in alkaline media above pH 9.0 due to disulfide reactions now being 
favorable.  Limiting the HMWP formation is the reason nearly all commercial injectable 
insulin formulations are currently formulated at neutral pH.  Even though the rate is 
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slowed, appreciable amounts of CID’s form so that the limit specified for insulin 
injectables by the U.S. Pharmacopeia can be exceeded (not more than 1.5%) and the 
product lifetime may be limited by this rate.  There is strong evidence that the incidence 
of immunological responses to insulin may result from the presence of these covalent 
aggregates of insulin (Robbins et al. 1987). In general, deamidation of Asn-B3 is the 
primary hydrolysis product noted at neutral pH in aqueous-based insulin formulations.   
The HMWP products at neutral pH are formed mainly by intermolecular aminolysis 
between N-terminal amines especially B1 and amide side chains in the insulin A-chain.  
The maximum stability of aqueous insulin formulations is observed around neutral pH.  
Brange states that most of the chemical instability of insulin is related to the 
conformational flexibility in the B1 – B8 section of the insulin molecule. Any increase in 
the rigidity of the N-terminal B chain via increased interaction (promoting hexamer), or 
excipients like phenol which induces a helical structure in B1 - B8 will decrease the 
deamidation and covalent dimer reactions (Berchtold et al. 1999, Derewenda et al. 1989b, 
Blundell et al. 1972, Brange et al. 1994, Darrington et al. 1995).  The helical structure 
induced is called the TR transition. The T state is an extended linear state for the chain, 
and the R state is an alpha helix (Kim et al. 1992). The alpha helix can further stabilize 
the hexamer.  High concentrations of chloride ions can induce the R state as well 
(Derewenda et al. 1989a).  Phenol has proven so powerful at stabilizing the B1 chain and 
promoting hexamer formation that nearly every injectable insulin formulation now 
contains it along with zinc. In the solutions used for this study it is assumed the B1-B8 
chain is in the extended T state, as no phenol is present and chloride ions are well below 
6% concentration.   
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In neutral solutions as well as crystals the covalent dimer formation is a result of 
inter-hexamer reactions, as the B1 N-terminal from one dimer is in close proximity to the 
reactive transamination sites on the A chain of an adjacent dimer. The transamination 
reaction exchanges the amine group from B1 or A1 to a side chain amide groups such as 
A15 Gln, A18 Asn, and A21Asn, and during the reaction ammonia is released. This led to 
the investigation presented in this thesis.  The theory was put forth that reducing hexamer 
contacts while maintaining non-covalent dimer in the solution just before spray drying 
would decrease CID formation, thus increasing dry powder chemical stability.  Figure 4 
shows the dimer and the points where another dimer contacts to form a hexamer, which 
allows the N-terminals access the reactive groups on the A chain. 
Figure 4: An insulin dimer, showing the dimer to dimer contact points within the 
hexamer. The red balls represent zinc placement in the center of hexamer. 
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Amorphous spray dried powder formulations can improve chemical stability compared to 
aqueous formulations (Franks 1994, Duddu et al. 1997, Hancock et al. 1997). In addition, 
Pikal demonstrated that amorphous lyophilized insulin powder was more stable than 
crystalline insulin powder (Pikal et al. 1997).  In 2007 Pfizer obtained FDA product 
approval for a 60% insulin formulation (Exubera) with a 2 year shelf life at room 
temperature, proving the excellent stability that spray dried amorphous powders can 
achieve.  
The main degradant Asn-B3 observed in aqueous formulations at neutral pH is 
dramatically decreased in the spray dried powders (Exubera, data not shown), and the 
powders predominant hydrolysis product at neutral pH is deamidation at Asn-A21.  The 
deamidation of Asn-B3 proceeds via formation of a cyclic imide-intermediate to form 
aspartic acid and iso-aspartic acid, so the absence of Asn-B3 deamidation in insulin 
powders is likely the result of decreased flexibility of the B-chain in the high viscosity 
microenvironment afforded by the amorphous dry state. Low moisture content, less than 
5% is usually required to achieve very stable amorphous glass states.  Since A21 is the 
C-terminal and has considerable freedom, deamidation proceeds through an anhydride 
intermediate, and becomes the main degradant in the spray dried powders. 
The covalent dimer formation rate is also decreased in the dry powder state, compared to 
solution state, but not as dramatically as B3 deamidation rate.  The spray dried insulin 
powders typically have moisture levels around 3-6 %.  The low level of water is probably 
of two fold importance.  As a consequence of low water levels, less reactant is available 
for the hydrolysis reactions; in addition the low water content reduces the molecular 
mobility of the insulin molecules (Brange 2000a, Strickley et al. 1996, Derewenda et al. 
1989a). 
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1.1.1 Spray Drying Method 
During spray drying the equilibrium state of hexamers and non-covalent dimers is 
essentially locked-in as the drying rate is so rapid it limits any translational movement of 
the insulin molecules. Spray drying time from droplet formation to powder particle is 
estimated to be approximately 200 – 400 milliseconds, depending on the type of spray 
dryer.  As the micro-droplets diameter shrinks with loss of water the large insulin 
assemblies are not expected to change the surfaces exposed to each molecule during 
drying.  Water, hydrophobic interaction of nonpolar groups, and hydrogen bonding are 
essential components in how dimers and hexamers form.  The secondary, tertiary, and 
quaternary structures all change slightly when water is extracted from protein structures. 
Even so, the Exubera powders have demonstrated that the formulation and spray dying of 
insulin do not change insulin’s physico-chemical properties. Temperatures are typically 
85°C or less on the dry powder in the collectors. Upon reconstitution the insulin 
re-assembles immediately to dimers and hexamers with no insoluble fibrils or aggregates 
detected.  The bioactivity is fully retained, and no denaturation is found.  The 
chromatogram in Figure  demonstrates the excellent chemical stability of insulin before 
and after spray drying. 
For pure USP grade zinc insulin, the crystal structures have extensively been shown to be 
hexamers (Wood et al. 1975, Baker et al. 1988, Kadima et al. 1991, Pullen et al. 1975, 
Brange et al. 1987). When the crystals are dehydrated down to 5% moisture the x-ray 
diffraction pattern demonstrates the insulin is in the amorphous state indicating no long 
range order, and yet the crystal morphology is completely maintained Figure  and 6.  It is 
the dehydration to less than 10% RH that causes the x-ray artifact, as protein 
crystallographers usually mount crystals from saturated solutions (~30% RH) for analysis. 
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Figure 5: XRD Pattern of Pure Insulin Crystals, 2 Zincs Per Hexamer, 5% Moisture.  
Crystal structures produce sharp peaks by XRD, and there are no peaks 
observed, and yet below Figure 6, we clearly observe the crystal structure. 
 
 
 
Figure 6: SEM of pure USP insulin crystals, 2 zinc per hexamer, 5% Moisture. 
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Figure 7: Insulin Injected on C18 RP-HPLC, chromatograms are zoomed in with 
very high magnification to view very small degradant peaks.  Change in 
main peak purity (24 minutes) is about 0.05%.  The peak at 39 minutes is 
the 0.05% additional impurity in the ASD (After Spray Drying) 
chromatogram.  ASD chromatogram is the dry insulin powder 
reconstituted with water after spray drying process.  BSD (Before Spray 
Drying) is the insulin crystals dissolved in a simple phosphate buffer. 
 
 
 
Figure and Figure illustrate how the insulin molecules are too large too change position 
translationally during the dehydration process.  The apparent crystal lattice is maintained, 
but very small movements of secondary and tertiary structures have occurred when the 
crystal is dehydrated to less than 10% moisture, leading to amorphous x-ray pattern.  
Spray dried powders will have some similar behavior as the dehydration process 
proceeds. Structures such as non-covalent dimers and even hexamers will not have time 
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to dissociate and the faces involved in the hydrophobic interactions will stay in close 
proximity until frozen in the glassy state.  This is strongly supported by stability studies 
as the crystal insulin and spray dried amorphous powders contain exactly the same 
covalent dimer species as degradants even though the crystalline rates of formation are 
faster.  Since the CID’s are mostly formed from inter-hexamer contacts this again 
supports the supposition that dehydrated hexamer-like structures are present in dry 
powder particle if it was present in the solution. 
1.1.2 Insulin Hexamer Formation 
An estimate of the hexamer state in solution is important for any process of handling 
insulin. Several scientists have tried to approximate a model for describing the 
equilibrium of insulin in solution (Blundell et al. 1972, Kadima et al. 1993, Kadima et al. 
1992, Pocker et al. 1981, Pocker et al. 1980, Lord et al. 1973).  This model is very 
complex as the population of every species from monomer to dimer to tetramer to 
hexamer will be a distribution percentage.  The concentration and type of buffer, along 
with pH, add complexity such that variables of specific models can no longer be 
decoupled or related to other buffer systems. In addition, most analytical techniques can 
only measure the average molecular weight of a protein, with distribution only implied.  
Furthermore, the surface energetics in the dimer interactions is stronger than the energy of 
three dimers that form the hexamer (Falconi et al. 2001, Jeffery et al. 1986, Goldman et 
al. 1994). In other words, the hexamer dissociates more easily to dimer than the dimer 
dissociates to monomer.  This model is extremely difficult to describe especially when 
zinc is involved (Mark et al. 1990).  Figure 8 is one representation of a possible 
equilibrium model, with six equilibrium constants to be considered. The extreme 
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complexity becomes apparent when buffer conditions affect each equilibrium constant 
independently. 
Figure 8: Population equilibrium model for insulin assembly.  M = monomer, D = 
dimer, T = Tetramer, and H = Hexamer.  Each arrow represents an equilibrium constant. 
 
For practical and functional reasons many researchers simplify the discussion to the 
average observed molecular weight of the solution, and the average number assembly 
state. For this thesis the average number or apparent molecular weight is discussed as 
well.  The distribution of species is assumed to be narrow, as the molecular weight 
approaches hexamer.  As the hexamer begins to dissociate the number of different species 
present will be broadest, as monomers, dimers, and hexamers could be present.  If dimers 
are mostly dissociated to monomer, the distribution is again very narrow and apparent 
MW of 5808 Da will be measured.  The basic thrust is that a solution composed mostly of 
hexamer will have an apparent molecular weight of 34,842 Da, which equals 5807 Da 
multiplied by 6.  The additional 2 zinc ions will add 130 Da (65 Da multiplied by 2).  The 
theoretical total for a complete solution of 2 zinc hexamer insulin will be 34,972 Da. If 
50% of the hexamers dissociate to dimer, (11,614 Da per dimer) and almost no monomer 
is present, the apparent molecular weight in solution then becomes 18,142 Da. This is the 
relative change in MW that will support estimating levels of dissociation of the hexamer. 
To measure the apparent molecular weights and estimate the assembly, the techniques 
that have been used are HPLC-SEC, mass spectrometry, membrane osmometry, 
M D T H
19 
sedimentation equilibrium (analytical centrifugation), as well as dynamic and static, light 
scattering. The most modern technique of multi-angle light scattering, permits 
measurement of the solution properties including their non-covalent oligomeric states 
with minimal physical intrusion on the sample.  While a sedimentation equilibrium run 
may require 72 hours, a light scattering study may be completed in well under an hour, 
and a batch mode analysis in a few minutes.  Dynamic light scattering can only offer 
hydrodynamic radius which requires interpretation, but offers more concentration 
flexibility.  The short run times coupled with the absolute determination of molar mass 
and comparatively low statistical error made multi-angle light scattering the method of 
choice for this experiment. 
Previous unpublished data demonstrated slight improvements in chemical stability of 
spray dried insulin powders with an increased pH of 7.6 versus of a 7.0 pH. To confirm 
the theory that a reduced hexamer population during spray drying would reduce covalent 
dimer formation, four powders were created by varying levels of zinc and including 
2 different pH values.  Additionally, the MALS (Multi Angle Light Scattering) technique 
was applied to a set of similar insulin solutions to study how strong the effects of pH and 
zinc content were on the self assembly of insulin.  The data supports the hypothesis that 
high pH and low zinc create the most stable spray-dried powder and that the low hexamer 
population is correlated to the improved stability. 
1.2 Experimental 
Four powders were prepared at a ratio of 90% mass of insulin to 10 % mass of buffer salts 
in the final dry powder listed in Table 2.  The powders were created to be put on a 
stability study at 50°C, while maintaining the original moisture content of 5% to maintain 
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the high glass transition (Tg) temperature (~ 85ºC) of the amorphous spray dried powders.  
The concentration during spray drying was 15 mg/mL of solids, which translates to 13.5 
mg/mL of insulin.  The approximation of 1% Na+ ion in the final powder reflects the 
additional sodium hydroxide used for pH titration. Since the USP insulin crystals produce 
an acidic pH, base is required to adjust pH to 7.8 before spray drying.  The ionic strength 
of the solution is approximately 15 mM. 
Table 2: Formulations of 90% Insulin Powders 10% Buffer, Spray Dried at 
15 mg/mL Total Solids, Correlated to 13.5 mg/mL of Insulin 
Powder pH
Zn / Insulin 
(g/g) Zn / Hexamer
%
Glycine
%
NaCitrate
%
Mannitol
(NaOH)
% Na+ 
A 7.8 0.01% 0 0.5 7.4 1.4 0.7 
B 7.8 0.14% ~ 1 (0.7) 0.5 7.4 1.4 0.7 
C 7.8 0.38% 2 0.5 7.4 1.4 0.7 
D 6.6 0.38% 2 0.5 7.4 1.4 0.6 
 
The powders were prepared in two batches; powder A and B were prepared from one 
solution and C and D were prepared identically but in separate flasks. All solutions used 
the same USP grade components of sodium citrate dihydrate (J.T. Baker), mannitol 
(Mallinckrodt), glycine (J.T. Baker), and recombinant human insulin crystals (Hoescht 
Marion Roussel) containing 0.38% zinc by mass, (on a dry basis) and 2 M sodium 
hydroxide (J.T. Baker).  For the powders A and B the goal was to produce a zinc-free 
insulin solution. A 600 mL solution of 90% insulin was prepared at 30 mg/mL total 
solids.  The pH was 7.6 for the chelation run.  To extract the zinc II ions an Alltech 
chelation column was used (Alltech data sheet 30250U).  The column is a resin (styrene 
divinylbenzene) with IDA (iminodiacetate ion) functional groups.  Each cartridge can 
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remove 0.5 milliequivalents of zinc II ion in exchange for a sodium ion at a pH above 5.0.  
The columns are equilibrated in NaCl solution before use.  The insulin crystals contain 
1 mole of zinc to 3 moles of insulin.  The solution concentration of insulin is 27 g/L or 
4.65 mM, since zinc is one third the concentration of insulin; 4.65 mM multiplied by 
1/3 gives the zinc concentration of 1.55 mM (or 101 μg/mL).  The total moles of zinc 
present is 1.55 mM multiplied by 0.3 L which is 0.465 mM.  One column should remove 
all the zinc.  Since insulin competes for the zinc, three chelation columns (3 times the 
required capacity) were placed in series to create strong binding potential for the zinc.  
The solutions were pumped through the columns at 1 mL/minute using an HPLC pump. 
ICP-AES (Inductive Coupled Plasma Atomic Emission Spectroscopy) was performed on 
the samples before chelation and after chelation for zinc concentration determination 
(courtesy of Dr. Fred Xi, Nektar Therapeutics, Huntsville, AL). The data proved the 
chelation was incomplete.  Only about 60% of the zinc was removed.  To help dissociate 
zinc from insulin the chelated solution was diluted to 15 mg/mL, final volume is now 1.2 
L, pH was rechecked and adjusted to 7.8, and one half (600 mL) was spray dried.  This 
was powder B (1 zinc per hexamer). The other half of the solution (600 mL) was rerun 
through a new set of chelation columns. The second run at the more dilute condition was 
more efficient, as zinc concentration was reduced to 1.6 μg/mL, essentially zinc free.  
Table 3 summarizes the samples and zinc concentrations.  The second half of the solution 
was spray dried at 15 mg/mL and pH 7.8, and is labeled as zinc free powder A. 
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Table 3: Zinc Content of Each Solution Before and After Chelation 
Original Solution 
No Chelation Pass First Pass 
First Pass 
2x Dilution 
Second Pass
2x Dilution 
Expected or Target 
(μg/mL) 95 0* 19.5 0* 
Actual measured by 
ICP-AES (μg/mL) 91 39 19.5 1.6 
*0 is target concentration for complete removal. 
 
Summarizing and relating the zinc content data back to the formulations in Table 2.  The 
most important concept is the ratio of moles of zinc to moles of insulin hexamer. The 
91 μg/mL in the starting solution is as expected.  It is slightly low probably due to a slight 
excess of water used in preparation when 2 M sodium hydroxide is added, and is 
insignificant error. This solution concentration represents 2 zincs per hexamer when 
insulin is about 27 mg/mL.  After the first pass the concentration of zinc is reduced to 
39 μg/mL, while insulin is still about 27 mg/mL.  A 2% dilution error of insulin probably 
occurred due to the 3-4 mL of solution used in priming the chelation columns.  
Nevertheless, the loss of 60% of the zinc content reduces the zinc to about 0.7 zincs per 
hexamer.  Since the concentration of zinc was 39 μg/mL the 2 times diluted sample used 
for recheck would have an expected concentration of 19.5 μg/mL which was the actual 
measured value.  Finally the second pass solution had a concentration of 1.6 μg/mL. This 
reflects that 96.5% of the original zinc has been removed. 
The solution preparation for powder C and D was straightforward.  The solutions were 
prepared the same as the A and B in that the insulin, sodium citrate and mannitol were 
weighed into a dry flask, and then water was added to bring the concentration to 
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15 mg/mL total solids.  After about 120 minutes of low level stirring, pH was adjusted to 
7.8 for C, and 6.6 for D. 
The powders were spray dried on a Buchi 191 spray dryer at a liquid feed rate of 
5 mL/minute, and an outlet temperature between 60-65°C.  The powders were free 
flowing low density, and approximately 3-5 μm MMD particle size, which is typical of 
Buchi spray dryers. 
The residual moisture levels of the powders were measured by TGA (thermo gravimetric 
analysis), using a TA Instruments (New Castle, DE) TGA.  Briefly, the powders were 
sealed into pans and heat was ramped to 130°C at 2°C/minute.  The weight lost is water 
content escaping as vapor through a small hole in the pan. The four powders all ranged 
from 3.4% to 4.4% loss on drying.  Previous unpublished data suggests less than 8% 
moisture is ideal moisture content for insulin powders to maintain stability. 
The accelerated stability study was delayed (due to resource constraints) and the powders 
were kept in a dry box at less than 10% RH at 18°C for 9 months before any analytical 
methods were performed.  The T = 0 HPLC results demonstrate no degradation occurred 
at these conditions, because the starting purity is identical to the starting insulin crystal 
material.  At 98.5% main peak purity the powders were ideal for an accelerated stability 
experiment. 
1.2.1 Evaluation/Characterization Methods 
To evaluate the accelerated stability samples a well characterized C-18 RP-HPLC method 
was chosen.  It is a method based on the European Pharmacopeia’s method for purity of 
human insulin. The data was generated using the following method.  The RP-HPLC 
24 
method used an ACE (Mac-Mod Analytical Chadds Ford, PA) C-18, 3 x 250 mm column.  
Mobile phase A consisted of 7% acetonitrile 140 mM sodium perchlorate, and the pH was 
adjusted to 2.3 with phosphoric acid.  Mobile phase B consisted of 57% acetonitrile, 
65 mM sodium perchlorate, and the pH was adjusted to 2.3 with phosphoric acid. The 
initial starting condition is isocratic at 55% B for 30 minutes, then a gradient to 80% B 
until 55 minutes.  At 56 minutes mobile phases return to starting conditions.  Flow rate 
was 0.55 mL/minute.  The HPLC is a Waters (Milford, MA) module with diode array 
detector.  The detector was set at 214 nm. Samples were prepared at 2 mg/mL insulin 
concentration and 10 μL was the injection volume.  Duplicate injections were made and 
integrated areas were averaged. 
To plot the stability data, Figure 13 defines the peak assignments for the chromatogram. 
These peak assignments have been compiled from many sources.  Novo Nordisk 
published an article in 2003 using this RP-HPLC method and defined the degradation 
peaks and regions.  Figure 12 shows the Novo Nordisk HPLC method used which also 
confirms the regions used for this study (Hvass et al. 2003).   
To further confirm the covalent dimer region, SEC (size exclusion chromatography) was 
performed on a slightly degraded insulin sample.  The method used a Zorbax GF-250 
column with a mobile phase consisting of 69% 0.4 M NH4HCO3 and 31% acetonitrile, 
pH 7.3 (Figure 9). The first eluting SEC peak was collected and cross injected on the 
RP-HPLC method and Novex SDS non-reducing electrophoresis tricine gel kit Figure 10. 
This experiment produced one band at 12,000 Da on the gel.  Peak 2 was confirmed as 
one band at 6000 Da. Peak 3 was later identified as citrate salt.  The HPLC method 
showed only the last seven peaks in 45 – 50 minute region for peak one of the SEC 
collection Figure 11.   
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Figure 9: Zorbax GF-250 column with a mobile phase consisting of 69% 0.4 M 
NH4HCO3 and 31% acetonitrile, pH 7.3. 
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Figure 10: Novex tricine gel with molecular weight standards, showing the insulin 
dimers and insulin monomers separated by the SEC-HPLC.  Peak 3 is 
citrate from the formulation. 
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Figure 11: C18 RP-HPLC method demonstrating the covalent dimer regions 
confirmed by SDS Gel and SEC-HPLC. The dimers were the fraction from 
peak one of the SEC collection. The monomers were the main peak of the 
SEC collection run. 
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Figure 12: Chromatogram confirming covalent dimer region by Novo Nordisk, 
courtesy Dr. Aage Hvass.  Essentially the covalent dimers are the last group 
of peaks eluted on most C18 RP-HPLC methods.   
 
 
This confirms the covalent dimer can be tracked very accurately by C-18 RP-HPLC. To 
simplify the analysis for this thesis, 8 areas were integrated. Insulin degradation products 
are too numerous to track individually, so they are grouped into regions.  The main 
degradant peak within each region is used to name that region Table 4. 
 
Figure 13: General regions of insulin degradation products defined on chromatogram 
for the 90% insulin powder using ACE column. 
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Table 4: Regions of Chromatogram Tracked by Stability Study.  
Region
Name B3 Main Peak A21 Hydrolysis 
Covalent
Dimer
Retention 
Time (min) 14 - 18 20 - 23 23 - 25 26 - 45 45 - 50 
Description 
B3 Asn 
Deamidation Insulin 
A21 Asn 
Deamidation
Insulin 
Related 
Hydrolysis 
Products 
Covalent 
Insulin 
Dimer 
 
Approximately 100 mg of each powder were transferred to 4 mL borosilicate glass vials 
sealed tightly with teflon lined caps. The T= 0 HPLC data was generated the same day the 
vials were placed in a 50°C lab oven.  While the stability samples incubated a method 
was developed to assess the hexamer assembly state of each.  
1.2.2 MALS Technique 
The MALS method development will be described in full detail in Section 2.7.2.  The 
MALS technique has been elevated recently as a high quality analytical tool, a direct 
result of the Wyatt Technology Corporation’s (Santa Barbara CA) commitment to the 
technology.  Wyatt’s strong technology integration efforts, coupled with continued 
advances in laser technology and computing power, make their instruments a must have 
tool for size measurements.  The fundamental physics are extensively described in the 
scientific literature and application notes, which are available at www.wyatt.com.  Figure
14 was obtained from Wyatt, and illustrates the basic operation. The polarized 690 nm 
laser light is continuously run through the flow cell which also contains the infused 
sample.  The flow cell is arrayed with 18 light detectors to measure scattered light 
intensity. The first step is to measure baseline scattering with a blank sample.  The blank 
contains all the solvents except the molecule of interest.  The sample is then flowed 
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through the cell and scattered light is increased, and based on the different intensity 
measured at all angles 0 through 180 degrees, the size and mass of the molecule can be 
calculated as a function of scattering intensity versus angle. Figure 15 is a sample run 
confirming identical insulin concentrations with decreased scattering as pH increases. 
Figure 14: Simplified diagram of MALS instrument showing only two detectors.  The 
actual flow cell is arrayed with 18 different detectors at discrete angles to 
monitor light scattering intensity as a function of angle. 
 
 
The samples for the MALS technique could not be run at the same concentration as the 
spray dried solutions. The limitation that proved difficult to overcome was the 
pre-filtration of the insulin solution. The system is extremely sensitive to interference 
from dust, contamination, air bubbles, and oils, each of which generates noise in the 
signal. To minimize noise the solutions are filtered through 0.02 μm, Whatman Anatop 
syringe filters.  Initial tests at 5 mg/mL of insulin clogged the filters.  Flow could not be 
maintained and the signal was generally unstable.  The filters were switched to 0.1 μm 
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pore size and flow was maintained, but the signal was not stable enough. For this 
experiment to proceed easily, insulin concentration was lowered to the 1-2 mg/mL range.  
The higher concentration samples can be undoubtedly be made to work with additional 
effort. 
Sample preparations were done in 150 mM sodium chloride and 10 mM TRIS (referred 
from here on as the dilution buffer).  A large 100 mL solution was prepared at 4 mg/mL 
of insulin, and 1000 mL of the dilution buffer was prepared. One half of the insulin was 
run over three chelation columns in series.  Based on previous data the zinc was assumed 
to be completely removed.  The sample set was designed to be 9 solutions of 
3 concentrations at 3 different pH values.  Samples were diluted to target and verified by 
UV spectrophotometer. The extinction coefficient of 1.05 (mL/mg) *cm-1, was used as 
the method for concentration determination of insulin in the 0.5 to 1.8 mg/mL range, in 
simple buffers.  The same set of 9 samples was created with the zinc-free insulin as well 
for a total of 18 samples.  Table 5 summarizes the solutions. 
Table 5: MALS Samples Numbered 1 to 9.  One set (zinc free) and 1set 
(2 zinc/hexamer) for a total of 18 sample data points. 
Concentration (mg/mL) pH 6.6 pH 7.6 pH 8.6 
1.0 1 2 3 
1.5 4 5 6 
2.0 7 8 9 
 
The solutions were prepared in 8 mL aliquots infused using 20 mL syringes, with no 
rubber components. A 0.02 μm filter followed by PEEK (polyetheretherketone) HPLC 
lines connected to the entry port of the flow cell of the Wyatt DAWN EOS light 
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scattering instrument.  The laser is 690 nm and 30 mW of power.  The measured flow rate 
was about 0.3 mL/minute through the flow cell.  This was achieved by slow infusion with 
an electric syringe pump.  All these parameters were designed to optimize and enhance 
signal stability. 
Figure 15: Example of light scattering run with insulin solution infused.  Each plateau 
is a new solution at the identical concentration with only the pH adjusted.  
This run is actually samples 4, 5, and 6, (no zinc, 1.5 mg/mL) from the 
matrix in Table 5.  The Y axis is the voltage of the 90 degree detector.  
Increased voltage indicates more scattered light detected.  The lowest 
scattering plateau is for pH 8.6 at 100 minutes. 
 
Large molecules scatter light more efficiently; the scattering intensity is monitored 
continuously at all angles.  By entering a few variables in the ASTRA software provided 
with the Wyatt instrument, a debye plot is generated from the data and computes the 
molar mass of the sample.  A much more extensive discussion of the molecular weight 
calculation is discussed later. 
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1.3 Results 
The MALS data is consistent with expected values.  Molar masses peak within 5% of the 
hexamer’s theoretical mass. This demonstrates that hexamer is the predominant species in 
this range of concentrations at neutral pH. Concentrations would have to be near the limit 
of solubility for hexamer stacking to occur.  At neutral pH this would be around 
50 mg/mL.  Table 6 and Table 7 summarizes the 2 zinc per hexamer insulin’s apparent 
molar mass and average assembly state.  Table 8 and 
Table 9 contain zinc-free insulin’s apparent molar mass and assembly state. Figures 16 
and 17 are the data from Table 6 and 7 plotted, and shown graphically. The average 
assembly state is a calculation that appears in most insulin literature that discusses the 
hexamer. It is the apparent molar mass divided by insulin monomer mass of 5808 Da. The 
number 6 represents all hexamers as the only species present.
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Table 6: Apparent Molar Mass (Da) of 2 Zinc Per Hexamer by MALS 
Concentration (mg/mL) 
pH
6.6 7.6 8.6 
1.0 33990 31310 22150 
1.5 34690 32960 27870 
2.0 35480 34210 30320 
 
Table 7: Average Assembly State of 2 Zinc Per Hexamer by MALS 
 Concentration (mg/mL) 
pH
6.6 7.6 8.6 
1.0 5.9 5.4 3.8 
1.5 6.0 5.7 4.8 
2.0 6.1 5.9 5.2 
 
Table 8: Apparent Molar Mass of Zinc Free Insulin by MALS 
 Concentration (mg/mL) 
pH
6.6 7.6 8.6 
1.0  27550 23570 17720 
1.5 32670 26880 20630 
2.0 34910 27150 21390 
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Table 9: Average Assembly State of Zinc Free Insulin by MALS 
 Concentration (mg/mL) 
pH
6.6 7.6 8.6 
1.0 4.7 4.1 3.1 
1.5 5.6 4.6 3.6 
2.0 6.0 4.7 3.7 
 
The 2 zinc per hexamer solutions appear to be almost complete hexamer at pH 6.6 and 
2 mg/mL. A shift in the basic direction of one pH unit to 7.6 only slightly depressed the 
apparent molar mass about 3%. As the pH shifts to 8.6 the apparent molar mass now 
decreases strongly, to about 21% smaller than pH 6.6.   
For the zinc-free insulin solution set, again the hexamer manages to predominate at 
pH 6.6 and 2 mg/mL but the dramatic suppression of hexamer assembly becomes obvious 
at pH 7.6, depressed from starting by 22% and can only assemble to about 21,000 Da at 
pH 8.6 a depression in MW of about 40%, at the highest insulin concentration of 
2 mg/mL. 
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Figure 16: 3-D plot of molar mass insulin solutions containing 2 zincs per hexamer. 
6.6
7.6
8.6
1
1.5
2
15000
20000
25000
30000
35000
40000
MW Da
pH
Conc mg/mL
Insulin 2 Zn/Hexamer
 
 
Figure 17: 3-D plot of molar mass insulin solutions containing no zinc. 
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Figure 18: Extrapolation curves of the effect of concentration on hexamer assembly 
of 2 zinc/hexamer solutions in 150 mM sodium chloride. 
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Figure 19: Extrapolation curves of the effect of concentration on hexamer assembly 
of zinc free solutions in 150 mM sodium chloride. 
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To correlate this low assembly effect to the spray dried powder’s solution concentration 
becomes difficult because the concentration parameter is not linear, but the experiment 
indicates that concentration has minimal driving force on hexamer assembly above 2 
mg/mL. From Figure 18 and 19 the rough log equation generated by the MW as a 
function of concentration from the zinc free plot, suggests at 13.5 mg/mL and pH 8.6 the 
apparent MW would be 31,000 Da, a clear overestimate. All of the equations have poor 
fits to the points, with R-squared values of 0.87 and below. The equations clearly 
overestimate the assembly on all the curves, as all 2.0 mg/mL points fall below the curves 
suggesting a plateau where hexamer assembly decreases as concentration increases.  
Important supporting data is supplied by W Kadima et al. (1993), in the article titled “The 
influence of ionic strength and pH on the aggregation properties of zinc-free insulin 
studied by static and dynamic laser light scattering,” in Biopolymers.  Figure   Kadima’s 
figure describing how increasing pH strongly dissociates the hexamer, while increasing 
concentration hits a plateau around 9 mg/mL and the assembly of hexamer is difficult to 
achieve even at 20 mg/mL in zinc free solution at pH 7.5. In retrospect the 150 mM 
sodium chloride is at the high side of the pharmaceutically relevant values. Ionic strength 
was not plotted by Kadima, but 4 data points of insulin at 2mg/mL and 4mg/mL were 
extracted from his experiments, and plotted in Figure 20.  The linear plot is only to show 
trend because each is only two points. This explains the higher association states in the 
MALS data produced in 150 mM sodium chloride.  This is easily understood as the 
charge-charge repulsion between surfaces is shielded by the negative and positive ions. 
Incidentally, Kadima’s paper contains a solution point within the study at 14 mM ionic 
strength, 12.6 mg/mL insulin, and pH 7.5 with an apparent molar mass of 19,819 Da.  
This is nearly identical to the conditions in solution for the spray dried powder A, except 
the pH was 7.8 in powder A, pushing the hexamer population even lower. 
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Figure 20: Kadima’s figure confirms the plateau with increasing insulin 
concentration, and the strong dissociation of hexamer with increasing pH 
in zinc-free solution. (Kadima et al. 1993) 
 
 
Figure 21: Kadima’s data showing the moderately strong effect of ionic strength on 
promoting the hexamer assembly in zinc-free solution. (Kadima et al. 
1993). 
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Even though the ideal data set of a direct MALS measurement on the solution  before 
spray drying the powders of A, B, and C was not done, sufficient data is presented to 
estimate the assembly states while spray drying.  Summarizing the state of the spray dried 
powders is presented in Table 10. Starting with the assumption of a complete hexamer 
state in solution, the percent of hexamers dissociated is also estimated. This supports the 
theory that insulin in the spray dried powder A (zinc free solution) is much less than 
hexamer during spray drying.  Conversely the zinc containing solution, Powder C, will 
clearly be driven into complete hexamer during spray drying. 
Table 10: Summary of the Association State of the Spray Dried Powders 
Powder pH 
Zn / Insulin
 (m/m) 
Zn / 
Hexamer
Estimated
Assembly
Number*
% Hexamer 
A 7.8 0.01% 0 3.1 50 
B 7.8 0.14% 1 (0.8) 4.0 67 
C 7.8 0.38% 2 6.0 100 
D 6.6 0.38% 2 6.1 100 
*Based on Kadima’s plot of MW versus concentration at pH 7.5 Figure 20. 
The insulin stability study demonstrates the dramatically improved stability of the 
formulations with less zinc and higher pH.  Figure 23, 24, 25 and 26 are plots of the 
HPLC data. Each region in Table 4 is plotted for each powder at 3 timepoints, initial, 
(0 weeks), 13 weeks, and 27 weeks, at 50°C. In addition, the actual integrated 
chromatograms are displayed in Figure 27, 28, and 29. This is to demonstrate the 
extreme care taken in the integration over 6 months.  Only one sample for each powder 
was prepared from the stability ovens. For each powder, 5 to 10 mg were reconstituted to 
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exactly 2.0 mg/mL insulin concentration.  Injection volumes were 10 μL, each sample 
was injected twice to increase confidence in the integration areas. The relative standard 
deviation (RSD) of the degradation product HPLC areas are estimated at approximately ± 
5 %. 
Great care was taken to create this precision.  It was obtained by using the same HPLC 
system, the same column, and the same carefully stored mobile phase, for the entire life 
of the study.  Injecting the exact consistent amount of protein on the column all lead to 
the ability to show the pattern growth visually with the stacked overlays.  Very careful 
manual integration was done at the end of the stability, starting with the final timepoint, 
so each region could be treated identically to the final timepoint. This builds confidence 
in the data, without doing dozens of injections and sample preparations for each 
timepoint. 
Figure 4: 90% insulin powder stability – B3 deamidation rate of 4 powders at 50°C
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Figure 23: 90% Insulin Powder Stability – Main Peak Purity of 4 Powders at 50°C 
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Figure 24: 90% insulin powder stability – A21 deamidation of 4 powders at 50°C  
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Figure 5: 90% insulin powder stability – hydrolysis product formation of 4 powders 
at 50°C. 
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Figure 6: Covalent insulin dimer formation rate of the 90% insulin powders at 50°C. 
90% Insulin Powder Stability 
Covalent Insulin Dimer Formation of 4 Powders at 50°C 
0.3
0.5
0.7
0.9
1.1
1.3
1.5
1.7
1.9
2.1
0 5 10 15 20 25 30
weeks
%
 o
f T
ot
al
A 0 Zn
B 1 Zn
C 2 Zn
D 2 Zn pH 6.6
 
43 
Figure 7: T = Zero weeks chromatograms for 50°C stability study. 
AU
-0.0005
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
0.0040
0.0045
Minutes
12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00
17
.3
99
19
.2
2 6
23
.9
36
29
.0
70
31
.2
96
40
.7
49
43
.7
51
48
.2
35
AU
- 0.0005
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
0.0040
0.0045
Minutes
12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00
17
.2
55
1
9.
09
9
23
.7
22
28
.8
17
30
.8
27
40
.6
01
44
.1
8
1
48
.1
87
A
U
- 0.00 0 5
0 .00 00
0 .00 05
0 .00 10
0 .00 15
0 .00 20
0 .00 25
0 .00 30
0 .00 35
0 .00 40
0 .00 45
M in utes
12 .0 0 1 4 .0 0 1 6.00 18 .00 20 .0 0 22 .0 0 2 4.0 0 2 6.00 2 8 .00 3 0.00 32 .00 34 .0 0 3 6.0 0 3 8.00 40 .00 42 .0 0 4 4.0 0 4 6.00 48 .00 5 0 .00
17
.1
52
18
.9
3
23
.5
1
28
.4
91
30
.5
61
40
.5
52
43
.6
63
48
.1
79
AU
- 0.0005
0.0000
0.0005
0.0010
0.0015
0.0020
0.0025
0.0030
0.0035
0.0040
0.0045
Minutes
12.00 14.00 16.00 18.00 20.00 22.00 24.00 26.00 28.00 30.00 32.00 34.00 36.00 38.00 40.00 42.00 44.00 46.00 48.00 50.00
17
.1
46
18
.9
86
23
.5
55
28
.6
07
29
.9
22 40
.5
15
43
.6
75
48
.1
87
0.23 98.47 0.79 0.12 
0.40 
0.21 98.46 0.80 0.12 
0.42 
0.16 98.46 0.81 0.11 
0.43 
0.16 98.29 0.94 0.12 
0.48 
A
B
C
D
 
 
44 
Figure 8: T = 13 weeks chromatograms 50°C stability study. 
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Figure 29: T = 27 weeks chromatograms for 50°C stability study. 
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1.4 Conclusion 
It is quite conclusive from the above data that all degradation products in the 90% insulin 
formulations are improved as the zinc is removed. It is highly improbable that zinc was 
behaving as a catalyst for any of these reactions.  The parameters of the experiment were 
controlled so only the variable was the assembly state of the insulin. This confirms the 
theory that reducing hexamer population in a dry powder can substantially reduce the 
covalent insulin dimer reactions as well as most degradation products. The optimum level 
of  hexamer dissociation was not determined. The main mechanism of dissociation 
appears to be the loss of the proton on B1 N-terminus amine. Since it is positively 
charged at pH 7, it associates and forms a possible ionic interaction or hydrogen bond 
with the negatively charged carboxyl group on Glu A17 in the adjacent noncovalent 
dimer.  At pH 7.8 the amine is approximately 50% deprotonated and will become neutral, 
thus losing the possible hexamer stabilizing interactions. This is discussed more 
thoroughly in the final conclusions in Chapter 4. 
The area of dissociating hexamer is open to further research, but the great value of high 
level pH control is proven. The data suggests that 50% of the hexamer remained and 
could be further dissociated even in the zinc-free solution. Other possible modes 
dissociation could be lower concentration of insulin, a pH of 8.5, and incorporation of 
small concentrations of organic solvents, like ethanol in the solution, during spray drying.  
The powders do not have to be used for inhalation; this technique can be used to simply 
produce a dry powder that can stabilize insulin for many years if kept dry.   
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2 ION EXCHANGE OF INSULIN AND PEGYLATED INSULIN
2.1 Introduction 
Modifying insulin to manipulate the physical and chemical properties has been a very 
active field of research and development for the last 30 years.  As soon as recombinant 
DNA technology enabled the production of synthetic human insulin from E.coli, 
scientists began experimenting with amino acid substitutions, deletions, and additions.  
For example in the article “Monomeric Insulins and Their Experimental and Clinical 
Implications” Jens Brange lists some properties of about 35 different analogues in 1990 
(Brange et al. 1990).  With the advent of PEGylation of proteins the number of insulin 
derivatives conceived is easily in the hundreds (Harris 1992, Delgado et al. 1992, 
Beauchamp et al. 1983).  Analytical methods and characterization of the derivatives can 
be complex and must evolve as a standard course. 
This experiment focuses specifically on the addition of a molecule of small PEG 
[poly(ethylene glycol)], and an acetyl moiety, to human insulin, and the ramifications on 
purity determination in chromatography.  Since the derivitization process is an organic 
reaction which uses an activated linker, the reaction with insulin proceeds through 
multiple pathways generating a mixture of derivatives.  Analytical characterization of the 
mixtures was very difficult because the differences between derivatives were subtle.  
Several scientists have been synthesizing a variety of PEGylated insulins (Caliceti et al. 
1999, Dou et al. 2007, Hinds et al. 2000b, Hinds et al. 2002, Uchio et al. 1999, Veronese 
et al. 2001, Calceti et al. 2004, Liu et al. 1997). The synthesis and purification procedures 
used can be complex.  These investigators have used many techniques to evaluate the 
purity of the chosen derivative (Delgado et al. 1997).  If an HPLC method could identify 
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and quantify the amount of derivatives in an experiment, various reaction chemistries 
could be evaluated and optimized in days instead of months of orthogonal methods. The 
ion exchange methods presented here can improve the simplicity and quality of the purity 
confirmation.  To properly assign specific physico-chemical properties to a specific 
derivative, the researcher must assure himself there are no substantial contaminants or 
leftover derivatives from side reactions. Usually, most researchers are satisfied with a 
level of 90% purity for the main component.  However care must be taken with new 
derivatives using older methods designed for the parent molecule. The methods may 
separate the unreacted parent molecule from the derivative, but may not be powerful 
enough to separate the multiple mono-PEG or di-PEG derivatives individually.  The ion 
exchange methods offered here can compliment the arsenal of methods required to ensure 
purity of the derivatives. 
2.2 Experimental 
2.2.1 Derivitization of Insulin 
The reaction components for the derivitization of insulin were as follows: Humanized 
porcine insulin by Akzo Nobel (Diosynth, France), an “activated” mPEG-succinimidyl 
propionate 750 to 5000 Da by Nektar Therapeutics.  For acetylation of insulin, acetic 
acid-NHS (N-hydroxy succinimide) (ICN Biomedical) was used.  For some reactions 
acetylation was performed first then the acetylated insulin was further PEGylated in a 
second step.  
The reaction conditions were carried out in an aqueous/organic solvent system with 
specific pH control to produce high yields of specific derivatives.  Conditions can be fine 
tuned for each derivative, but the use of an organic solvent to slow the competing side 
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reaction of ester hydrolysis with water was used. The pH of 7 - 10 is used to selectively 
deprotonate the reactive primary amines on A1, B1, and B29. 
For the acetylation reaction, insulin was dissolved at 40 mg/ml in the aqueous phase with 
50 mM boric acid, the pH was adjusted to 9.0 with 2 M sodium hydroxide and stirred 
until the solution was clear. The solution was diluted to 45% DMSO and 55% aqueous 
phase.  The Acetic acid NHS was dissolved separately in DMSO at 23 mg/mL.  2.5 moles 
of Acetic acid NHS to 1.0 mole of insulin was calculated and added to the insulin 
solution.   The reaction was allowed to proceed for about 15 minutes.  The solution was 
“quenched” by dilution with water to 2 mg/mL insulin concentration, and pH was 
adjusted to 7.5 with 1 M hydrochloric acid.  PEGylation reactions were similar. These 
reactions are fully described in World Intellectual Property Organization, international 
patent, number WO 2010 033220, titled “Modified Therapeutic Peptides, Methods of 
Their Preparation and Use” by Nektar Therapeutics, 25 March 2010. Additional teaching 
in the state of the art is described by Eli Lilly’s United States Reissued Patent number US 
RE37,971E, titled “Selective Acylation of Epsilon-Amino Groups”, 28 January 2003. The 
patent describes dozens of mixed organic solvent systems for acylating B29 Lys of 
insulin, using esters.  
Despite all the advancements in reaction control, side reactions occurred for all 
procedures and produced mixtures that required purification and quantitation. Some 
derivatives were made at large-scale and purified by large-scale cation exchange 
chromatography, while smaller scale procedures used C-18 RP-HPLC for purification. 
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2.2.2 Matrix Assisted Laser Desorption Ionization (MALDI) Mass 
Spectrometry  
The matrix used for the Mass Spectrometry samples was sinapinic acid.  The Voyager 
DE-Pro was operated in the linear mode, with positive ions monitored.  The 337 nm line 
of the nitrogen laser was used with about 200 shots averaged for the final spectrum.  The 
spectra were produced by M-Scan Inc. of West Chester, PA. 
2.2.3 RP-HPLC 
The RP-HPLC method used a Superspher (EM Science) C-18, 4 μm, 3 x 250 mm 
column.  Mobile phase A consisted of 7% Acetonitrile 140 mM sodium perchlorate, and 
the pH was adjusted to 2.3 with phosphoric acid.  Mobile phase B consisted of 57% 
acetonitrile, 65 mM sodium perchlorate, and the pH was adjusted to 2.3 with phosphoric 
acid. The initial starting condition is isocractic at 55% B for 30 minutes, then a gradient to 
80% B at 55 minutes.  Flow rate was 0.55 mL/minute.  The detector was set at 214 nm.   
2.2.4 Ion Exchange Chromatography 
Cation Exchange: A GE Healthcare Mini-S PE 4.6 x 50 mm column was used. Two 
mobile phase systems were employed.  For system 1, mobile phase A consisted of 40% 
acetonitrile and 1 M acetic acid.  Mobile phase B consisted of 40% acetonitrile, 1 M 
acetic acid, and 300 mM sodium perchlorate.  The gradient was 1% B at 0 minutes to 
80% B at 20 minutes.  The flow rate was 0.8 mL/minute.  The detector was set at 276 nm.   
For system 2, mobile phase A consisted of 30% acetonitrile, and 0.1% TFA.  Mobile 
phase B was 30% acetonitrile, 0.1% TFA and 300 mM sodium perchlorate. The gradient 
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was 0% B 0 minutes to 80% at B at 20 minutes.  The flow rate was 0.8 mL/minute.  The 
detector was set at 214 nm, and 276 nm. 
Anion Exchange: A GE Healthcare Mini-Q PE 4.6 x 50 mm column was used.  Mobile 
phase A consisted of 20% acetonitrile 50 mM Tris at pH 8.8.  Mobile phase B consisted 
of 20% acetonitrile 50 mM Tris 300 mM NaCl at pH 8.8.  Gradient was 0% B at 
0 minutes to 80% B at 20 minutes.  Flow rate was 0.8 mL/minute.  The detector was set at 
276 nm.  The pH was modified as needed from 7.0 to 8.8 with sodium hydroxide. 
All chromatography work was performed on a Waters 2690 pump with photo diode array 
detector, or an Agilent 1200 system with variable wavelength detector. Sample 
concentrations were approximately 0.2 mM and injection volumes 10 to 50 μL. 
2.3 Results and Discussion 
2.3.1 Derivitization Mixtures 
One of the most common reactions used to derivatize proteins is an activated ester which 
reacts with primary amines.  The primary amines of insulin are the A-chain N terminus 
(A1) the B-chain terminus (B1) and the lysine side chain on B29.  Acetic acid-NHS was 
used for acetylation, and PEG-succinimidyl propionic acid (PEG-SPA) for PEGylation.  
The NHS was chosen for high specificity and fewer side reactions, as opposed to 
anhydrides or other moieties (Lindsay et al. 1971).  When these activated esters 
covalently react with the insulin amines the mono, di, and tri-derivatives result.  In 
addition, Table 11 shows how this process creates multiple sub-species of mono, di and 
tri-derivatives.  To assess yields of such reactions requires a reliable method that can 
quickly separate all of the sub-species of conjugated insulin. 
52 
Table 11: Potential Mixture of Seven Species of Insulin Generated from 
Derivitization Process 
Insulin
Species Mono-derivatives Di-derivatives Tri-derivatives 
Insulin 
Sub-species A1 B1 B29 A1-B1 A1-B29 B1-B29 A1-B1-B29 
 
2.3.2 Cation Exchange of Acetylated Derivatives 
To assess reaction kinetics a mixture of acetylated insulin derivatives was created by 
reacting 3 moles of acetic-NHS with 1 mole of insulin in an aqueous/organic solution 
with no pH control.  The reaction conditions produced a mixture of tri-acetylated insulin, 
two different di-acetylated derivatives, and one mono-acetylated derivative Figure 30. 
The mono, di and tri- acetylated species were confirmed by fraction collection and 
subsequent analysis by LC-MS. The mixture was used to optimize the cation exchange 
method using the Mini-S column. 
The Mini-S column and a classical cation exchange mobile phase were evaluated.  Mobile 
phase A consisted of 7 M urea and 1 M acetic acid, and mobile phase B consisted of 7 M 
urea 1 M acetic acid, and 300 mM NaCl (Calceti et al. 2004). The gradient was 0% B to 
80% B in 20 minutes. The pH is estimated to be around 3.0. The peak shapes were very 
poor Figure 30 A. Acetonitrile was used to replace the urea as a chaotropic agent.  The 
peak shapes and retention were greatly improved Figure 30 B.  The final mobile phase is 
listed in the previous methods section as mobile phase system 1 for cation exchange, 40% 
acetonitrile and 300mM sodium perchlorate, and 1 M acetic acid which had a pH of 2.3. 
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Figure 30: The same mixture of acetylated insulin species on Mini-S cation exchange 
column using two different mobile phases.  Chromatogram A is an older 
method using 7 M urea, Chromatogram B is using acetonitrile and 
sodium perchlorate, both in 1 M acetic acid.  The acetonitrile mobile phase 
(B) demonstrates improved retention and much better peak shape.  Sodium 
perchlorate is used because of increased solubility versus sodium chloride 
in acetonitrile. 
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2.3.3 RP-HPLC and Cation Exchange on a PEGylated Insulin 
Mixture 
A randomly PEGylated insulin mixture was created by reacting 2.5 moles of PEG-SPA 
(750 Da) with 1 mole of insulin in a mixed solvent (organic/aqueous) solution with no pH 
control.  MALDI mass spectra were generated on the final 750 PEG insulin reaction 
mixture Figure 31.  The MALDI finding confirms that only mono-PEG and di-
PEGylated insulin species are present.  Insulin at 5808 Da plus 750 Da PEG is 6558 
(main peak), and 5808 plus 1500 Da (2 PEG chains) is 7308 (second peak).  In addition, 
the spectra show the expected normal distribution of longer and shorter chains of PEG 
attached.  PEG chains vary by 44 Da for each PEG unit, but the average molecular weight 
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of this sample is a 750 Da PEG chain attached at each conjugation site. The MALDI  data 
shows the individual distribution of 44 Da peak steps,  providing a qualitative view of the 
average distribution of the PEG polymer attached. 
The randomly 750 PEGylated insulin was injected on RP-HPLC and the Mini-S cation 
exchange method Figure 32 A and Figure 32 B. The powerful resolution of cation 
exchange allows quantitation the sub-species mono-PEG A1 and mono-PEG B29, which 
was not resolved by RP-HPLC or MALDI.  The MALDI confirms no free insulin. 
Figure 31: MALDI mass spectrum of the randomly PEGylated 750 Da PEG-insulin.  
The molecular weight confirmation is important for interpreting the 
chromatograms.  This data is only qualitative but confirms approximately 
50% each of mono and di-PEG insulin species, but no information about 
the sub-species derivative types. 
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Figure 32: The same mixture of randomly PEGylated (750) insulin on two different 
methods.  Chromatogram A is by C-18 RP-HPLC and shows only mono 
or di species.  Chromatogram B is by cation exchange and demonstrates 
how the mono-PEGylated component is composed of 2 different sub-
species which are not resolved by C-18 RP-HPLC. 
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2.3.4 RP-HPLC Peptide Map 
The peak assignments in the cation exchange chromatogram were assigned through a 
series of peptide mapping experiments using the USP (United States Pharmacopiea) 
peptide mapping test for human insulin.  The method essentially cuts the insulin into four 
fragments, and fortuitously each derivitization site is isolated on one fragment. Figure 33 
shows how the Staphylococcus aureus V-8 protease cuts the insulin at glutamic acid 
residues, and leaves the disulfide bonds intact. If the site is derivatized, the fragment 
elutes later by RP-HPLC, and the degree of site derivitization can be quantitated by 
comparing it to a reference standard. Figure 34 is an example of a Di-Ac B1 2K PEG 
insulin digest elution pattern run on the RP-HPLC method.   
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Figure 33: The USP fragments by staphylococcus aureus V8 protease. Fragment I 
consists of A5 to A17 and B1 to B13. Fragment II behaves like control and is never 
derivitized, and it consists of  A18 to A21 and B14 to B21. Fragment III consists of B22 
to B30.  Fragment IV consists of A1 to A4. 
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Figure 34: The USP V-8 digest fragments of insulin and Di-Ac B1 PEGylated insulin 
by RP-HPLC confirming where the insulin fragment I has been derivatized by PEG and 
elutes much later. The acetylated fragments IV (A1) and III (B29) change by 2 - 5 
minutes and the fragment II is unchanged in retention time. 
 
 
 
2.3.5 Anion Exchange of PEGylated and Acetylated Insulin 
Derivatives
As various PEG-insulin derivatization schemes were conceived and synthesized, an 
insulin derivative acetylated on A1 and B29, and PEGylated on B1 became a molecule of 
interest because it had the longest PK by intratracheal instillation in a preclinical rat study 
(data not shown).  Referred to as (B1PEG di-Ac), a 5K and 2K version were synthesized 
and purified.  This triply derivatized insulin had poor retention by cation exchange Figure
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35.  Evaluation of the molecule reveals that there are only 3 of the original six positive 
charges remaining compared to insulin, for an overall net charge of plus 3 at pH 2.0. 
A decrease in overall positive charge explains why it eluted very near the void volume in 
about 1-2 minutes. 
To proceed rationally to the anion exchange column, the theoretical charge state versus 
the pH of a tri-derivitized insulin, a mono derivative, and non-derivatized insulin were 
plotted in Figure 36.  The plot was created using standard pKa values of the free amino 
acids that compose insulin (Voet et al. 1990).  The B1 PEG di-Ac insulin, (Figure 35), 
red lower trace) showed that at pH 7.0 to 8.0 has an overall charge of negative 5.  
Theoretically, the derivative should be retained by the anion exchange column more 
effectively.  To leverage this overall more negative state, the derivative’s behavior was 
evaluated on the anion exchange column Figure . The system provided excellent 
retention and was further developed. 
Figure 35: B1PEG(5K) di-Ac insulin on Mini-bead cation exchange column, system 
2 mobile phase (TFA), showing retention time of 1 minute on the column.  
mono-derivatives were retained well on this system. 
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Figure 36: Theoretical curve of the charge state of insulin and two derivatives of 
insulin.  The tri-derivatized state (red lower curve) suggests a pH of 
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approximately 8.0 will achieve (-5) overall charge state and should be 
retained well on the anion exchange column at that pH.   
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Figure 37: Anion exchange Mini-bead column with same sample as Figure 35, 
(B1PEG(5K) di-Ac insulin) demonstrating excellent retention and the 
ability to resolve small impurities using pH 7.8 mobile phase. 
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2.3.6 Anion Exchange Mobile Phase pH Optimization 
Three main derivative types were constructed for preclinical experiments (data not 
shown).  Mono PEG on B29 of insulin, Mono PEG on B1 of insulin, and Mono PEG on 
B1 with di-acetylation, one (acetylation) on B29 and one (acetylation) on A1.  The anion 
exchange method was optimized to ensure purity of each derivative. 
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When the Mono-PEG B1 was injected on the anion exchange column, it demonstrated 
very poor retention and peak shape Figure 38. To optimize the behavior, the 
mono-PEG’s theoretical charge vs. pH curve Figure 36 was again referenced.  The graph 
shows the mono derivatives of insulin can be pushed from net (-3) charge at pH 7 to near 
net (-5) charge at pH 9. The mobile phase was adjusted upward to pH 8.8, to drive the 
negative charges toward saturation.   
The three main types of 5K PEG-insulin derivatives were injected.  The improved 
chromatograms at pH 8.8 vs. pH 8.3 mobile phase were generated in Figure 39.  Also of 
note is the resolution of additional peaks in the B1 mono–PEG lots, indicating some 
residual B29 and tri-derivatized species from the synthesis and purification procedure.  
Another important finding illustrated in the chromatogram in Figure 40 is the same 
derivative types, but with shorter length (2K) PEG chains.  They are notably more 
retained by the column by about 2 minutes.  This is another important tool for separation. 
Figure 38: 5K PEG insulin derivatives on anion exchange at pH 8.3.  The B1 mono 
PEG has very poor retention and shape.  
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Figure 39: Same samples of 5K PEG insulin as Figure 38, but with mobile phase pH 
adjusted to 8.8.  All samples have improved retention and shape, but 
mono-PEG B1 has dramatically improved. 
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Figure 40: Same Mobile Phase as Figure 39, but the Samples are 2K PEG Insulin 
Derivatives.  The samples are more strongly retained on the column versus 
5K PEG insulin derivatives. 
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2.3.7 Anion Exchange is Stability Indicating 
Pure lyophilized powder of mono-PEG B1 Di-Ac 2000 (2K) insulin was put in a 50°C 
oven for 20 weeks. The peaks were not specifically characterized, but the standard 
hydrolytic degradation products such as covalent dimers and deamidation products are 
expected to be the main degradants. The anion exchange resolved these products even 
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with the PEG attached Figure 41. The C-18 RP-HPLC (not shown) did not have any 
clearly resolved peaks.  For the anion exchange the purity for T = 0 was 97.3% main 
peak.  For T = 20 weeks, the purity was 93.8%. The main degradant at 12.5 minutes was 
2.9%, and due to the high charge and high retention, is most likely PEGylated covalent 
insulin dimer. 
Figure 41: Zoomed chromatogram on anion exchange method is T = 0 of 2K mono 
PEG B1 di-Ac insulin.  Bottom chromatogram is the 20 weeks at 50°C 
sample, demonstrating excellent resolution of the degradants.  The peak at 
12.5 minutes is most likely PEGylated covalent insulin dimers. 
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2.4 Conclusions 
By carefully evaluating the physical and chemical properties of the molecule, in this case 
PEGylated insulin, the chromatographic conditions were designed to enhance peak shape, 
selectivity, and retention to generate the data required. 
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The clustering or asymmetry of the charge distribution on insulin may be  an important 
property from this exercise.  The ion exchange clearly separates these derivatives with 
better than expected resolution.  Part of this selectivity on the anion exchange is related to 
the pKa differences between underivatized lysine side chain pKa 10.8 on the B1 
derivative, and the B29 derivative, which has the B1 N-terminal pKa of 8.0.  To explain 
the resolution, approximately 10% of the positive charge remains on the B1 and A1 
amines, because to be fully neutralized the pH needs to be 2 units above the pKa.  At pH 
8.8 the well retained Tri-derivative has all positive charges neutralized and is -5.  The 
B29 derivative has the 2 N-terminal amines 90% neutralized and has a charge of 
approximately -4.8 . The B1 derivative has the completely positive Lys and 90% of the 
A1 amine neutralized and is about -3.9 charge state. The derivatives elute exactly 
according to the negative charge state, B1(-3.9), elutes, followed by B29 (-4.8), and 
finally Tri-derivative (Di-Ac B1PEG -5.0). This does not fully explain the excellent 
resolution between B29 and B1 Di-Ac, Therefore, the asymmetry of charges on the 
surface of the molecule, and the pKa of the underivatized sites combine to modify how 
the derivative interacts with the ion exchange media. This assumes that the insulin is in 
the monomeric state. The 20% acetonitrile assures this state is achieved. 
For the Anion exchange method, the charge state and charge grouping on the insulin 
molecule is the property that is dominantly used for separation, with increased PEG mass 
slightly decreasing or interfering with the retention. This data agrees well with other 
reported observations of the behavior of proteins and PEGylated proteins on the ion 
exchange columns (Dou et al. 2007, Liu et al. 1997, Lindsay et al. 1971, Seely et al. 
2005).  As PEG mass to protein mass ratio increases the retention is decreased, but for 
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certain configurations the charge state and position of the derivative can be the most 
important property.  
This is classic structure and function behavior.  By understanding the structure one can 
better predict the behavior.  Of course, investigators working with very large PEGs may 
see the PEG properties begin to overwhelm this chromatographic system.  Table 12 is a 
summary of how the HPLC methods relate to characterizing the molecules. 
Table 12: Method Summary 
Methods Cation 
Exchange
Anion
Exchange
RP-HPLC MALDI Mass 
Spec
Dominant 
Separation 
Mode 
Positive charge 
of insulin, less 
derivitized is 
retained better 
(best for mono 
derivatives) 
Negative charge 
of insulin, more 
derivatized is 
retained better, 
(best for tri 
derivatives) 
Increased PEG 
mass is retained 
regardless of 
site. 
Qualitative 
estimate of 
mono di and tri 
PEG state. 
 
It is also obvious that for each given peak in the anion exchange chromatograms the 
leading edge of the peak will contain the longest PEG chains and the trailing edge will be 
the shortest PEG chains.  So a PEG molecular weight distribution range is inferred within 
each peak, but strongly retained peaks appear to be narrower, so this is only a general 
behavior for an individual peak. 
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For the RP C-18 method, the hydrophobic property of the PEG moiety is the dominant 
separation property.  Therefore, increases in PEG to protein mass ratio will increase 
column retention.  Furthermore the PEG’s domination will mask subtle charge state 
changes such as a different site of derivitization or a degradant such as deamidation. 
It is important to note that the Mass Spectra data is crucial to interpreting the 
chromatographic data.  The presence or lack of presence of mono, di, and tri-PEG 
derivatives must be known ahead to maximize understanding of the chromatograms.  
Once the general pattern of elution has been systematically determined the ion exchange 
method becomes very useful for optimizing derivitization yields.  The method also 
appears to have great stability indicating utility for a chosen derivatize. 
Identifying the elution pattern of each derivative requires a combination of peptide 
mapping, MALDI mass spectra, and ion exchange chromatography.  It is important to 
acknowledge GE Healthcares advancement in column technology as well.  Future work 
could include a more detailed model of the charge grouping relative to the derivatives 
position to better understand why for example B1 is poorly retained compared to B29’s 
strong retention on the anion exchange column.  If the method had been developed ahead 
of time, much more efficiency in screening the reaction chemistries would have been 
enabled. Years were spent trying to attach PEG in a high yield, high purity format. For 
research, the utility of one screening method rather than four or five orthogonal methods 
would have provided high scientific and monetary value. 
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Association Patterns of PEGylated Insulin 
2.5 Introduction 
The PEG-insulin derivatives in this thesis were created to investigate the potential of 
PEGylation to prolong the pharmacokinetics of inhaled insulin. The underlying theory 
suggests that increasing the PEG chain length will increasingly slow the rate of diffusion 
of the insulin molecule across the lung into the underlying capillary bed (Niven et al. 
1995, Upton et al. 1999, Cherrington et al. 2004, Donovan et al. 1990). The success of 
Exubura inhaled insulin spurred the possible idea of long-acting insulin by the inhalation 
route.. Using the lung as reservoir or a depot to store insulin for up to 12 hours was a 
risky proposition. The lungs are more susceptible to irritation than subcutaneous 
injections, which also use the strategy of storing deposits of insulin in the dermis, which 
then leak slowly into the capillaries for many hours. Several preclinical inhalation trials in 
dogs successfully proved that many of the derivatives extended glucose lowering for 4 - 
24 hours after dosing compared to regular insulin (Patton et al. 2005a, Patton et al. 
2005b).  Figure 43 is a PK/PD plot from The Nektar patent WO/2010/033220.  Inhaled  
regular insulin clears the blood in about 4 hours. The  Di-Ac 2K PEG insulin shows 
lowered glucose for up to 15 hours by inhalation in dogs, thus demonstrating the lung 
reservoir concept. Possible lung risks coupled with high cost of goods halted the project.   
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Figure 42: The PK/PD profile of Di-Ac 2K PEG insulin in an inhalation study in 
dogs.  The insulin has the highest concentration of 10 ng/mL at about 2 hours, and returns 
to baseline at about 16 hours.   
 
 
 
Even though the overall aim of the project was to study the very complex inhalation PK 
and PD profiles, the fundamental physical and chemical properties of the derivatives are 
also of major interest and are the focus of this thesis. The basic structure of mPEG is 
shown in Figure 43.  The PEG insulin derivatives were made with methyl end-capped 
PEG’s (mPEG) to reduce reactivity after conjugation to the molecule. With a methyl 
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group on one end the remaining alcohol group is modified with the activated linker which 
attaches to the insulin molecule. 
 
Figure 43: Methyl Poly(ethylene glycol) structure (mPEG). The subscript n represents 
the number of repeating units of ethylene oxide. The repeating unit is 44 
Da, so 100 polymers synthesized together would have an approximate 
molecular weight of 4400 Da. 
 
HO—(CH2 CH2O)n—CH2 CH2OCH3 
To covalently attach PEG to insulin, the strategy was to attach it at the three primary 
amines of insulin with activated esters.  A variety of strategies were reviewed to 
synthesize and characterize each insulin derivative (Myers et al. 1997, Naithani et al. 
1982, Lindsay et al. 1971, Uchio et al. 1998, Beauchamp et al. 1982, Chap et al. 1987, 
Geoghegan et al. 1997, Hansen et al. 1978, Jones et al. 1976, Kaplan et al. 1976, Zalipski 
et al. 1992, Weider et al. 1979).  The strategies include linker chemistry, pH control, 
blocking, de-blocking, organic solvent mixtures, and purification steps.  A model of 
insulin with a PEG chain attached at all three potential attachment sites is shown in
Figure 44.  All PEG-insulins were manufactured using succinimidyl propionic acid linker 
on mPEG, and reacted with the primary amine on the specified amino acid. For this thesis 
no PEG was attached at A1, only an acetyl groups on some analogues.  All of the 
PEGylated insulin derivatives in this study only have 1 PEG attached per derivative, 
either at B1 or B29 only.   
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Figure 44: Porcine Insulin Model Showing Approximate Geometry of PEGs 
Covalently Attached to the Reactive Primary Amine Groups on Insulin. 
The PEG is represented by the black lines at the A1, B1, and B29 amino 
acids of insulin. The PEG is not proper scale.  The single difference 
between porcine and human insulin is the B-30 threonine of human insulin 
is replaced by B-30 alanine. The structure is representative of human 
insulin. 
 
A series of PEG derivatives were synthesized ranging in molecular weight (MW) size 
from 550 to 5000 Da PEG, and differing in attachment sites on B1, and B29 insulin 
amino acid positions. The focus for this thesis is the assembly patterns of the derivatives 
in simple formulation buffers with varied pH, and the development of the MALS method 
and associated techniques. 
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PEG is often referred to as a hydrophilic moiety; this is true, because in aqueous solutions 
it can tightly bind about 3 water molecules per repeating ethylene oxide unit (Harris JM, 
1992).  This leads to the ability to solubilize poorly soluble molecules when PEG is 
covalently attached. Even so, PEG also has high solubility in many organic solvents due 
to the ethylene units. A better description for PEG would be an amphiphilic moiety, 
giving it somewhat flexible and possibly unpredictable behavior. Pure PEG with no water 
content, is a waxy oil-like substance, but readily soluble in water.  As a basis to compare 
the PEG-insulin derivatives physico-chemical behavior, the published literature of several 
newly approved insulin derivatives were reviewed.  The noteworthy long-acting 
derivative of insulin of Levemir contains a hydrophobic fatty acid chain attached at the 
B29 of insulin. During the development of this now FDA approved insulin derivative, 
different sites of attachment were tried and dozens of different hydrophobic residues were 
attached to fine tune the properties (Whittingham et al. 2004).  Eli Lilly and Company 
also has a palmitoyl fatty acid insulin in development (Hashimoto et al. 1989, Myers et 
al. 1997).  The final configuration of the Levemir is a myristic acid attached to the B-29 
primary amine. Furthermore the B-30 threonine has been removed (Des B30). 
Interestingly, it would be expected for this derivative to have difficulty assembling to 
dimer or hexamer due to the bulky moiety attached, but as outlined in the thesis 
introduction this analogue unexpectedly forms large stacked hexamers. 
To proceed along a similar discovery path, the PEG-insulin derivatives fundamental 
properties need to be further explored and defined.  Theoretically, most derivitizations in 
the B29 area should reduce dimer formation. Since PEG is much more hydrophilic than 
fatty acids, the expectation is limited formation the hexamer and dimer. To investigate the 
PEG-derivatives association patterns the MALS technique was applied to a variety of 
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solutions. The batch mode, as well as SEC-MALS, were used to approximate any 
distribution patterns, as the MALS can give size information across the size exclusion 
peak.  In batch mode the average MW is measured, producing a single value for a 
concentration of bulk solution.  In SEC-MALS mode the MW is determined several times 
per second producing plot of MW versus elution volume. 
As discussed in the previous section, a strong effort was put forth to design each specific 
derivative and purify it to 95% or better by ion exchange chromatography and or 
RP-HPLC, as appropriate for each derivative. Various research groups within Nektar 
Therapeutics provided the insulin derivatives, and documentation of the purity. The 
synthesis and purification techniques are outlined in Chapter 2 of this thesis.  Other 
insulin types were also chosen as controls for certain methods. It was not possible to 
analyze every derivative in every method, as material was limited. 
 The naming convention chosen was as follows:  
1. Site of PEG derivitization (A1, B1, and B29). 
2. PEG size, MW in Daltons 
3. Secondary derivitization such as acetyl blocking groups. 
As an example the most complex derivative is B1 5000 Di-Ac (A1-B29).  The Di-Ac 
represents the attachment of an acetyl group on A1 and B29.  The acetyl was attached as a 
manufacturing exercise to block most reactive groups A1 and B29, so a 5000 Da PEG 
(occasionally referred to as 5K PEG) could then be attached to the least reactive B1 
group. The blocking groups are so small (43 Da) that they are simply left on the insulin 
molecule, saving a substantial amount of resources required for secondary de-blocking 
and purification steps.  This highlights an interesting general point, that in alkaline pH 
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B29 reacts first followed by A1 and finally by B1, and can be used to react each site 
individually by controlling the moles of ester added. This is one of the claims of Nektar 
patent WO/2010/03320.  Table 13 shows the list of insulin derivatives studied, along 
with MALDI data.  The MALDI analysis (outlined in Chapter 2) was a performed on 
every PEGylated insulin derivative to confirm a single point of PEG attachment.  The 
specific point was further confirmed by the USP identity test using Staphylococcus aureus 
V-8 protease.  The V-8 digests insulin into 4 fragments. Fragment I is A5-A17 disulfide 
linked to B1-B13, fragment II is A18-A21 disulfide linked to B14- B21, fragment III is 
B22-B30, and fragment IV is A1-A4.  When the insulin is derivitized, the fragments 
elution time on the C-18, RP-HPLC is changed (Chapter 2, Figure 34). 
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Table 13: Insulin Derivatives Used in the Various MALS Sizing Experiments 
Insulin Type MALDI Mass (Da) PEG Mass (Da) 
B29 750 6544 736 
B29 2000 8179 2371 
B29 3000 8844 3036 
B29 5000 11274 5466 
B29 2000 Di Ac (A1 B1) 8183 2375 
B29 Mono Ac 5852 44* 
B1 2000 8007 2199 
B1 3000 8755 2947 
B1 5000 11519 5711 
B1 2000 Di Ac 8150 2342 
B1 5000 Di Ac 11196 5388 
Novolog Asp B28 5826 0 
Humalog Lispro 5808 0 
Regular Insulin 5808 0 
 
2.6 Experimental 
2.6.1 Preliminary PEG-insulin Sizing Techniques 
A preliminary sizing technique was investigated using HPLC-SEC with a UV detector, 
and molecular weight standards. The standards were GE Healthcare low molecular weight 
standards for gel filtration. The SEC method used two Shodex KW802.5 in series.  They 
are standard gel permeation columns for proteins less than 150,000 Da. The media is a 
silica based bead with a hydrophilic end group. The mobile phase was 150 mM  sodium 
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chloride 10 mM TRIS, at pH 7.4. The flow rate was 0.6 mL/minute.  The wavelength 
monitored was 276 nm. The elution volume of the molecular weight standards and the 
resulting plot are in Table 14 and Figure 45.  Samples were 3 mg/mL and 40 μL 
injection volume. 
Table 14:  SEC Elution Volume Versus MW 
Standard MW (Da) log MW Time (min) Ve (mL) 
Ribonuclease 13700 4.14 30.03 18.02 
Chymotrypsin 25000 4.40 29.12 17.47 
Ovalalbumin 43000 4.63 24.43 14.66 
bsa 67000 4.83 23.00 13.80 
 
Figure 45: SEC plot of molecular weight standards Table 14 versus elution volume to 
determine equation used to determine association state of insulin. 
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The insulin derivatives chosen were the four different 2000 MW PEG samples.  Two 
monomeric insulin’s were run for controls.  All the insulin’s were diluted to 2 mg/mL 
protein concentration. Lilly’s Lispro and Novo Nordisk’s Novolog both dissociate rapidly 
to monomer and should plot out to 6000 Da for the assay and confirm the techniques 
utility. The results are presented in Table 15.  The association state is the apparent MW 
divided by the monomer MW. 
Table 15: Apparent Molecular Weights of Insulin and Insulin Derivatives 
Protein MW (Da) log MW time (min) Ve (mL) Assoc. State 
B29 2000 28000 4.447152 27.26 16.36 3.4 
B1 2000 29470 4.4693746 27.00 16.20 3.7 
B29 2000 Di Ac 27882 4.4453278 27.29 16.37 3.4 
B1 2000 Di Ac 27760 4.4434206 27.31 16.38 3.5 
Insulin 13728 4.1376117 31.00 18.60 2.4 
Asp B28 12809 4.1075117 31.36 18.82 2.2 
Lispro 11442 4.058506 31.95 19.17 2.0 
 
The technique has the potential to order the size of the molecules correctly, but the 
accuracy and precision is highly questionable.   Once the hexamer has dissociated the 
monomeric insulin’s Lispro and Asp B28 should have limited dimer formation.  The MW 
of 11,442 Da is not consistent with expectations for the monomeric insulin’s. For this 
technique the error is too large to generate useful data. In addition, the molecular weight 
standards do not bracket the samples. The smallest standard available was 13,700 Da. The 
insulin at 5808 Da is outside the linear range. Furthermore, the fit of the linear equation 
has an R2 value of 0.92, which is quite poor.  
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This data is supportive that the insulin assemblies (dimer) may be eluting on the SEC 
columns, and that a technique other than MW standards for determining the size may 
provide insight into the assembly behavior.  Therefore, more accurate sizing techniques 
were considered for this experiment. 
2.6.2 Experimental PEG-insulin Sizing by MALS 
The techniques considered were membrane osmometry, and ultracentrifugation.  The 
ultracentrifugation technique needs highly trained operators and the equipment is 
complex and it requires very long run times. Even so, some minor improvements such as 
digital data acquisition have been made to the technique recently (Lebowitz 2002).  The 
membrane osmometry data is number-averaged molar mass not the more useful 
weight-averaged molar mass.  Both techniques have approximately ± 15% rsd in 
accuracy, but have not significantly improved for 30 years. The MALS technique 
however has shown great improvement in accuracy and precision, and error is very good 
at approximately ± 5% rsd (Folta-Stogniew et al. 1999). The laser power, detector 
sensitivity, computer controls, and simplified analysis software, coupled with easy 
connectivity to HPLC systems have elevated the technique to the first choice in many 
sizing applications, (Kendrick et al. 2001, Attri et al. 2005, Ye 2006). Very little data on 
insulin assembly has ever been generated by the MALS technique, so this was an 
opportunity to contribute additional data on the subject (Oliva et al 2000).  In addition, 
the MALS technique can also be combined with SEC columns while the other two 
cannot. The MALS technique using Wyatt Technology’s instrument was chosen. 
Several instruments and modules are required to perform the analysis.  Figure 46 
(Courtesy Wyatt Technology) illustrates the setup used for the work presented here. 
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Figure 46: The analytical setup for generating MALS data.  The degasser, pump, 
in-line filter, injector, columns and UV detector, are present in a typical 
modern HPLC system. The RI (refractive index) detector, and DAWN 
(MALS detector) are simply attached downstream in the flow path of the 
HPLC system, and connected to a computer. 
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The exact instruments used were as follows:  
Agilent Technologies 1100 series HPLC; 
1. Quaternary pump. 
2. Degasser. 
3. Diode array UV detector. 
4. Auto-injector. 
5. Column oven. 
6. Chemstation software. 
78 
Wyatt Technology 
1. DAWN EOS light scattering instrument, (MALS) 
2. Optilab DSP refractive index detector. 
The MALS instrument can be run separately in batch mode, with no HPLC unit or 
column required.  The batch mode setup used in this chapter simply replaces the HPLC 
and column with a syringe pump. The modules used in this thesis are no longer available 
from Wyatt as several next generation instruments currently available have improved 
performance. 
To interpret the MALS data a discussion of the analysis software and physics is 
necessary.  The equations and discussions presented here are a summary of the extensive 
training literature available from Wyatt Technology.  The computation of the molar mass 
from the complex physics are enabled and simplified by the use of polarized laser light, 
but the mathematics are very complex.   
The effort for the following discussion is to simplify, and explain the equations used for 
the insulin assembly behavior.  The MALS technique can provide several different types 
of size related data that may not be useful for a given experimental setup.  Calculated 
outputs such as the radius of gyration (rg) are only valid for molecules larger than 10 nm. 
The second virial coefficient known as A2, is a measure of how strongly the molecule 
interacts with the solvent. A slightly positive number indicates a good solvent, and a 
negative value indicates the molecules are in danger of precipitation. For the insulin 
experiments the assumption was made that A2 will be slightly positive and not important 
to measure for this experiment. Water is a very good solvent for insulin, and the low 
concentrations make the correction factor A2 insignificant for this experiment. 
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The first important equation is the proportionality equation relating intensity of scattering 
to the molar mass. 
2
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I is the intensity of the scattered light, M is the molar mass, c is the concentration 
in g/mL, and dn/dc is the change of refractive index divided by change in concentration. 
If I is supplied from the MALS instrument, and the refractive index of the molecule in the 
solution is known, along with the concentration of the molecule, the molar mass can be 
calculated.  The dn/dc value for a molecule can be found in the literature or determined 
using the Optilab DSP module. Protein-protein interactions, like insulin hexamer or 
dimer, will cause the molecules to scatter light in a unit called a scattering center, and the 
assemblies’ average molar mass will be the calculated output.  There are several ways to 
report the mass of the polymer by MALS.  The type of experiment dictates the type of 
mass available. Fractionated samples such as SEC peaks, and unfractionated mixtures, 
such as a batch mode produce different mass numbers.  The molar mass moments are 
methods to quantitate polydispersed samples or samples containing a distribution of lower 
and higher weight molecules.  Figure 47 (courtesy Wyatt Technology) is a description of 
the three types of molar mass moments.  Mn is the average molar mass number and can 
bias or create error in the average mass by toward the highest population of an individual 
species.  Mz average is cubed and squared so it can bias the average mass toward the 
heavier weight fraction.   These 2 mass moments can only be determined in SEC mode. 
Mw called the average molar mass weight average is the data determined by the light 
scattering instrument and the other two values can by calculated by the Astra software if 
80 
required, but only when SEC data is generated and only if the separation of the molecules 
is of high quality.  Mw is the only number available when the MALS is run in batch mode.  
For this thesis only Mw is reported, because the combination of the PEG polymer size 
variation and the insulin assembly variation cannot be decoupled. 
Figure 47: Molar mass moments used for expressing possible size and potential 
polydispersity. 
 
For both modes of analysis, batch and SEC, the 2 major ways of extracting Mw and 
plotting scattering data, are a Zimm plot or a Debye plot. To briefly explain the plots the 
Rayleigh-Gans-Debye light scattering equation (courtesy of Wyatt Technology) is shown 
below. 
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K*c = 1 + 2A2cR(,c) MwP()
 
 
	 R(,c) is the excess Rayleigh ratio of the solution as a function of scattering angle 
 and concentration c. It is directly proportional to the intensity of the scattered 
light in excess of the light scattered by the pure solvent.  
	 c is the solute concentration.  
	 Mw is the weight-averaged solute molar mass.  
	 A2 is the second virial coefficient in the virial expansion of the osmotic pressure.  
	 K* is the constant 42(dn/dc)2n02/NA04.  
	 Na is Avogadro's number. This number always appears when concentration is 
measured in g/mL and molar mass in g/mol. 
	 P() describes the angular dependence of the scattered light, and can be related to 
the rms radius. 
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From this equation the plot variables for the Debye plot are shown in Figure 48.  The plot 
consists of K* c / R on the y-axis versus sin2(/2)  on the x-axis, and the slope of the 
18 detectors light scattering intensity gives the y intercept of 1/ Mw. 
Figure 48: Debye plot showing how molar mass is determined from Raleigh equation. 
 
The Zimm plot is simply an inverse plot of   R / K* c still on the y-axis versus sin2(/2) 
on the x-axis, and works well for multiple concentrations in batch mode. 
2.7 Results 
2.7.1 Measurement of dn/dc for Insulin 
The error related to computation of Mw is directly related to the dn/dc value used, thus a 
5% error in dn/dc value  creates 5% error in Mw, in SEC mode and in batch mode  is 
doubled 5% error in dn/dc will produce 10% error. It is important to obtain the best value 
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possible for insulin to reduce error. The wavelength of the laser is related to the dn/dc as 
well, as the wavelength increases the dn/dc decreases.  The only dn/dc value found for 
insulin was performed by P Doty, et al. (1952).  They reported a dn/dc value of 
0.202 mL/g using a laser wavelength of 436 nm. The modern modules used for this thesis 
use a 690 nm laser, so the dn/dc value will be lower.  Furthermore, it has been proposed 
that nearly all proteins will have the same dn/dc value of approximately 0.185 to 0.186 
(690 nm) and that it is independent of amino acid composition (Wen et al. 1996).  Since 
the Optilab DSP module is capable of measuring the refractive index (n) the dn/dc value 
of insulin was measured at 690 nm.  
The Optilab DSP was verified with 5 concentration levels of sodium chloride. The known 
dn/dc value of 0.172 mL/g for sodium chloride at 690 nm was reproduced exactly by the 
experiment. The technique is simple using a syringe pump, a syringe with no rubber 
components (Normject, 10 mL), and PEEK tubing with fittings to attach between the 
Optilab flow cell and the syringe. Flow rate was 0.2 to 0.3 mL/minute. Solutions were 
prefiltered through 0.1 μm inorganic membrane syringe filters. 
Seven concentrations of insulin were prepared, at 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, and 
0.8 mg/mL, in 150 mM sodium chloride 10 mM TRIS, at pH 7.5.  For each solution, the 
concentration was precisely determined by UV, using the insulin molar extinction 
coefficient of 1.05 mL/g cm-1 at 276 nm.  Each solution was infused until a stable signal 
was obtained. The raw data and the summary report of the calculated dn/dc is presented in 
Figure 49 and Figure 50.  The dn/dc determined from the experiment is 0.1844 mL/g 
± 0.004, and is in strong agreement with the proposal of J Wen et al. (1996) that most 
proteins should be about 0.186 mL/g at 690 nm. Wyatt training literature recommends 
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0.185 mL/g for proteins, therefore all the calculations in the thesis will use the dn/dc of 
0.185 mL/g at 690 nm for insulin. 
Figure 49: Raw data plot of refractive index versus concentration (dn/dc) of insulin. 
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Figure 50: Summary report from Astra calculating the dn/dc of insulin. The value is 
in the bottom left results section. 
 
2.7.2 Calculations of dn/dc for PEG-insulin 
Since the dn/dc value of insulin is established, the attachment of PEG will modify it, and 
for each insulin derivative it will need to be recalculated. Wyatt Technolgy’s training 
manual states that for block copolymers the final dn/dc is the weighted average of each 
polymers pure dn/dc.  This assumption was applied to the insulin derivatives, rather than 
measuring each, again because of limited material.  The new values will be a proportional 
interpolation of each pure components dn/dc value based on the mass ratio of insulin to 
PEG listed in Table 13. PEG’s dn/dc value is well established, a 5000 MW PEG has a 
dn/dc value of 0.141 mL/g at 690 nm. The math used to compute the dn/dc of the 
derivatives was to take the difference between the two values, 0.185 minus 0.141 equals a 
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range of 0.044, between the two pure components. The range is then multiplied by the 
weight fraction of PEG, that fraction of the range is then subtracted from the insulin 
dn/dc. As an example the B1 5000 is exactly 50% PEG and 50% insulin.  The range 
multiplied by the fraction is, 0.044 x 50% = 0.22, subtracting that value from 0.185 equals 
a dn/dc value 0.163 mL/g for that derivative, exactly half way between the two pure dn/dc 
values.  Table 16 is the calculated dn/dc values for the derivatives, as well as a 
concentration correction required to compensate for the UV assay, which only determines 
g/mL of insulin. The solutions were all prepared at the same molar concentration of 
insulin to compare assembly behavior, but PEG conjugation changes the solids 
concentration on a mass basis. The correction factor adds the mass of PEG to the 
concentration, which is needed for input in the Astra software for accurate MW 
determination.  
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Table 16: Insulin Derivatives dn/dc Calculations 
Insulin Type MALDI 
Mass
(Da) 
PEG
Mass
(Da) 
Weight 
Fraction of 
PEG
dn/dc (mL/g) 
Protein/PEG 
Complex 
Concentration
Correction 
Factor 
B29 750 6544 736 0.1125 0.180 1.112 
B29 2000 8179 2371 0.2899 0.172 1.290 
B29 3000 8844 3036 0.3433 0.170 1.343 
B29 5000 11274 5466 0.4848 0.164 1.485 
B29 2000 Di Ac (A1 B1) 8183 2375 0.2902 0.172 1.290 
B29 Mono Ac 5852 44 0.0075 0.185 1.008 
B1 2000 8007 2199 0.2746 0.173 1.275 
B1 3000 8755 2947 0.3366 0.170 1.337 
B1 5000 11519 5711 0.4958 0.163 1.496 
B1 2000 Di Ac 8150 2342 0.2874 0.172 1.287 
B1 5000 Di Ac 11196 5388 0.4812 0.164 1.481 
 
2.7.3 SEC-MALS 
The same SEC method described above was maintained, but the MALS and Optilab 
modules were attached instead of the UV detector.  The first experiments were to test 
controls that should have predictable behavior, and similar properties to the molecules of 
interest.  Free mPEG (Nektar) with an average MW of 5300 Da, by MALDI, which was 
also used to derivatize the PEG insulins, was used as a control. 50 μL was injected at 10 
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mg/mL on the SEC-MALS setup.  Lilly’s Humalog (Lispro) monomeric insulin was also 
used as a control, with an expected MW of 5808 Da. The concentration was 3.5 mg/mL 
and 25 μL was injected.  The Astra software plots the MW across the SEC peak versus 
elution volume.  Figure 51 is the free mPEG, and Figure 52 is the Lispro.  The Debye 
plot (not shown) reported an average Mw of 5325 Da for the free mPEG. The range of 
4500 to 6100 Da is the typical range for synthetic polymers, about a 10% distribution 
above and below the average MW.  Lispro insulin does show signs of assembling to 
dimer as the front of the peak is close to 7000 Da, but the trailing portion is the 5808 Da 
monomer.  The Debye plot reports average MW of 6360 Da.  Notice the elution volume 
of the mPEG, of 16.3 mL, and the 19.7 mL elution volume of the almost identically sized 
monomeric insulin. This confirms the SEC with molecular weight standards is not 
appropriate, as two components with nearly identical MW elute 3 minutes apart on the 
columns. This also confirms the MALS technique can produced data consistent with 
theoretical predictions on control samples. 
Figure 51: 5000 Da mPEG (no insulin) on SEC-MALS with Mw versus elution 
volume. 
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Figure 52: Humalog Lispro monomeric insulin on SEC-MALS Mw versus elution 
volume. 
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In another test of the technique 2 mg/mL insulin was injected at volumes of 20, 40, and 
80 μL Figure 53. It can be clearly seen the peaks elution volume changes with the 
increase of injected mass of protein. Figure 54 shows how increased concentration is 
causing the insulin to assemble. All underivatized insulin drug used throughout is 2 zinc 
per hexamer insulin crystal, unless otherwise noted.  The mobile phase contains no zinc 
therefore the insulin will be zinc-free and separated from the original 2 zinc ions.  The 
overlays clearly show insulin assembling to larger aggregates as the concentration 
increases, verified by MALS. 
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Figure 53: Three consecutive runs of insulin with increasing injection volume, 
showing decreasing elution volume, and increased MW with increased 
concentration. 
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Figure 54: Maximum observed MW is plotted versus the maximum concentration at 
the highest point of the SEC peak, obtained from the Debye plot in Astra 
software. 
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No hexamer is observed, and the dimer population (11,616 Da) predominates. The 
concentrations are slightly low for relating directly to formulation development, but the 
assembly state for the concentration range agrees well with the literature for zinc-free 
insulin in solution at pH 7.4, which is monomers assembling to dimer (Brange et al. 
1994). 
Even though the concentrations were lower than the concentration that creates hexamers, 
the derivatives that were modified at B29 were also injected at 3 levels of 20, 40, and 
80 μL, to judge how dimer assembly is affected by PEG chain length. The concentrations 
were all 2 mg/mL of insulin (0.334 mM), but a monomer will plot out at different MW 
due to the PEG size difference on each derivative.  Therefore the MW will be divided by 
the monomer MW to obtain the average assembly state at each concentration. As an 
example the B29 5000 raw data is presented in Figure 55. The monomer of this 
derivative is 11,270 Da. The highest MW from the plot is 17,000 Da, using the 80 μL 
injection volume. An example of the assembly state calculation is as follows:  
17,000 / 11,270  = 1.5 
1.5 is well below dimer assembly number (2.0).  This derivative is hindered in assembly 
by the PEG attachment.  Table 17 is a summary of the assembly state by injection 
volume. 
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Figure 55: Three increasing injection volumes of B29 5000 PEG insulin by SEC-
MALS. 
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Table 17: Summary of the Assembly State of B29 Insulin Derivatives as 
Concentration Increases with Larger Injection Volumes. The samples were 
injected at 2 mg/mL insulin concentration. 
Insulin type 
Monomer
MALDI mass 
(Da)
Average Assembly State by Injection Volume 
on SEC-MALS  
20 µL 40 µL 80 µL 
Regular Insulin 5808 1.6 1.8 2.1 
B29 Mono Ac  5852 1.0 1.1 1.1 
B29 750  6544 1.5 1.7 1.7 
B29 2000  8179 1.0 1.2 1.3 
B29 3000  8844 1.2 1.2 1.3 
B29 5000  11274 1.2 1.2 1.5 
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From Table 17, the B29 750 PEG behaves the most like regular insulin assembling  to 1.7 
at the highest concentration.  The concentrations were in the same range as the plot in 
Figure 55, about 0.1 to 0.18 mg/mL of insulin.  The run of 18 injections had some slight 
noise in the refractive index detector, which led to increased error in the MW 
determination at the lower concentrations.  Therefore the high assembly state of 1.5 for 
the B29 5000 PEG is within experimental error of 5% rsd. The conclusion from this set of 
data is the PEG at B29 interferes moderately with insulin assembling to dimer.  
For the next experiment the concentrations of the samples were increased to 9 mg/mL 
(insulin) and 50 μL injection volumes to see if dimers could be observed in the 
derivatives. All of the B1 derivatives were included in the run.  The highest concentration 
at the top of the peak is approximately tripled from the previous run, from 0.18 mg/mL to 
about 0.5 mg/mL insulin.  Table 18 is a summary of the assembly state at the maximum 
concentration of 0.5 mg/mL during SEC-MALS. 
Table 18: Summary of the Assembly State at the Maximum Concentration of 0.5 
mg/mL during SEC-MALS. 
Insulin type Monomer MALDI mass (Da) 
Average Assembly State 
by SEC-MALS 
Regular Insulin 5808 2.9 
B29 Mono Ac  5852 1.5 
B29 750  6544 1.9 
B29 2000  8179 1.6 
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B29 3000  8844 1.8 
B29 5000  11274 1.8 
B29 2000 Di Ac (A1 B1) 8183 1.4 
B1 2000  8007 2.0 
B1 3000  8755 2.2 
B1 5000  11519 2.3 
B1 2000 Di Ac 8150 1.6 
B1 5000 Di Ac 11196 1.7 
 
The data from the Table 18 shows the higher concentration of 0.5 mg/mL is driving all 
the derivatives to higher assembly states. Since B1 is not involved in the dimer interface 
the B1 derivatives have formed dimers, while any derivatization on B29 has reduced the 
dimer formation. 
2.7.4 Batch Mode MALS  
 
The next set of experiments was designed to test an increase in the concentration up to 
2 mg/mL insulin in the flow cell.  In addition the pH was varied to judge its effect on the 
assembly state.  This required a batch experiment, and the SEC columns were removed 
from the circuit.  Three specific concentrations were chosen and directly infused by 
syringe into the light scattering detector, with no dilution effect, as caused by the SEC 
columns. The samples were run in sets of three, comprised of one concentration at 3 
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different pH values. Each sample was loaded into a syringe with its own filter attached. 
During data collection the pump was stopped when the sample was done, and the next 
syringe was attached and the pump restarted.  Figure 15 (Chapter 1) shows a typical run 
with the air bubbles between each syringe switch out. The drawback is that no 
distribution information is obtained; only one average MW data point is available.  Four 
derivatives were chosen for zinc free conditions, and the B1 2000, and B1 2000 DiAc 
were also prepared with 2 zincs per hexamer. The buffer was 10 mM TRIS 150 mM 
sodium chloride, and pH adjusted with 2.0 M sodium hydroxide.  Zinc chloride was 
added to the designated solutions prepared at 2 mg/mL to produce an exact mole ratio of 
1:3 zinc to insulin. The solutions were then diluted with the buffer to the lower 
concentrations presented.  The solutions were filtered through 0.02 μm, Whatman Anatop 
syringe filters, using the technique described in Section 1.1.2. 
The assembly state data is presented in Table 19.  As a control the regular insulin data is 
also included (previously presented in Section 1). Unfortunately there was an insufficient 
amount of the drug B29 2000 to analyze with zinc included. 
Table 19: Assembly State of Insulin and PEG-insulin Derivatives as a Function of 
Insulin Concentration, Zinc, and pH by MALS 
Insulin Concentration 
(mg/mL) 1.0 1.5 2.0 pH 
Insulin (Zinc-Free) 4.7 5.6 6.0 6.6 
4.1 4.6 4.7 7.6 
3.1 3.6 3.7 8.6 
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Insulin Concentration 
(mg/mL) 1.0 1.5 2.0 pH 
Insulin (Zinc) 5.9 6.0 6.1 6.6 
5.4 5.7 5.9 7.6 
3.8 4.8 5.2 8.6 
B29 2000 3.3 3.6 3.8 6.6 
2.0 2.4 2.5 7.6 
1.6 1.7 1.8 8.6 
B1 2000 2.4 2.4 2.6 6.6 
2.0 1.9 2.1 7.6 
1.7 1.8 1.9 8.6 
B1 5000 2.5 2.5 2.6 6.6 
2.2 2.2 2.2 7.6 
1.2 1.8 1.9 8.6 
B1 2000 DiAc 1.7 1.8 1.8 6.6 
1.6 1.7 1.7 7.6 
1.5 1.5 1.5 8.6 
B1 2000 (Zinc) 5.5 5.3 5.4 6.6 
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Insulin Concentration 
(mg/mL) 1.0 1.5 2.0 pH 
5.4 5.2 4.9 7.6 
4.5 4.2 4.2 8.6 
B1 2000 DiAc (Zinc) 3.1 3.6 3.8 6.6 
2.6 2.9 3.4 7.6 
2.2 2.3 2.5 8.6 
 
It is difficult to spot trends in tabulated data, so graphical plots are presented in Figure  
Figure 56, 57, 58, 59, 60 and 61,. The B29 2000 is the most sensitive to pH. From pH 
6.6 to 8.6 dramatic dissociation from 3.6 down to less than the 2.0 dimer. The data shows 
that once the dimer is formed it can begin to form hexamer. The B1 2000 shows similar 
behavior at pH 8.6, almost able to form dimer, but the decrease of pH to 6.6 does not 
promote the hexamer as readily. B1 5000 does not differentiate itself from B1 2000. It has 
nearly identical behavior except at the lowest concentration and pH 8.6 it is close to 
monomer.  The B1 2000 DiAc strongly dissociates and is nearly insensitive to pH and 
concentration, and is unable to form dimers.   The final 2 plots now add the parameter of 
zinc which strongly promotes the derivatives to form higher aggregates.  The B1 2000 
which was approximately dimer and resistant to hexamer formation now strongly 
associates in the presence of zinc.  The B1 2000 DiAc which was even more resistant to 
any association shows similar behavior to B1 2000, and is strongly associated to 
approximately tetramer with zinc in solution. 
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Figure 56: Association state of B29 2000 PEG insulin with no zinc by MALS at 
pH 6.6, 7.6 and 8.6. 
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Figure 57: Association state of B1 2000 PEG insulin with no zinc by MALS at 
pH 6.6, 7.6 and 8.6. 
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Figure 58: Association state of B1 5000 PEG insulin with no zinc by MALS at 
pH 6.6, 7.6 and 8.6. 
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Figure 59: Association state of Di-Ac B1 2000 PEG insulin with no zinc by MALS at 
pH 6.6, 7.6 and 8.6. 
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Figure 60: Association state of B1 2000 PEG insulin with zinc by MALS at pH 6.6, 
7.6 and 8.6. 
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Figure 61: Association state of B1 2000 DiAc PEG insulin with zinc by MALS at pH 
6.6, 7.6 and 8.6. 
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2.8 Conclusions 
The derivitization at B29 does interfere with insulin’s ability to form dimer and hexamer. 
However, this interference is minimal. Dimers form as the concentration increases and the 
pH decreases, and as the zinc is added.  The association of the B1 derivative is similar to 
the B29 derivative, except the B29 does assemble into aggregates larger than dimer at the 
lower pH of 6.6. This would be related to the same mechanism further discussed in
Chapter 4, where the ionic bond between two dimers is promoted between the B1 N-
terminus and the A17 glutamate at pH values below 7.5.  Since the B1 is not available for 
hydrogen bonding in the B1 derivatives, the assembly state clearly levels off at about 2.5, 
which is low in hexamer. For insulin the hydrophobic surfaces interacting are the 
dominant forces for formation of dimer and hexamer, with hydrogen bonding, ionic 
interactions and zinc providing additional stabilizing forces.  The medium length PEG 
(2000 to 3000 Da) appears to interfere with ionic bonding and hydrophobic interaction. 
The derivitizations appear to be minor to moderate disruptions to assembly, because when 
zinc is added to the solution it appears to be a very powerful stabilizer driving the 
assemblies higher.  This validates Lilly’s approach to Humalog Lispro.  By the MALS in 
Figure 52 the Lispro is starting to form loose dimers with no zinc, but Lilly formulates 
with zinc and phenol which enables complete hexamer equilibrium in solution, which 
creates comparable shelf life stability to the regular insulin products.  So like Lispro 
hydrogen bond disruption and additional steric hinderance from the bulky PEG in the B29 
region can be over come with zinc.  The 5000 Da PEG on B1 causes a major disruption in 
hexamer, especially at pH 8.5 with no zinc.  Unfortunately, a complete comparison of 
B29 versus B1 5K with and with out zinc could not be accomplished. 
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3 OVERALL CONCLUSIONS
The main lesson from this thesis is that the use of zinc to stabilize hexamer is so powerful 
that pH and ionic interactions of insulin’s charged groups can become minor effects in 
stabilizing or destabilizing.  Even so, as the numbers of new insulin derivatives and 
formulations continue to grow, reviewing these subtle charge interactions for a particular 
derivative or formulation strategy can prove very fruitful for designing the final approach.   
If zinc and phenol need to be limited, these ionic interactions become very important. As 
precise control of excipients, and especially the ability to accurately measure pH continue 
to improve in laboratories, precisely controlling the pH of an insulin solution should be 
carefully and rationally designed.  Since most analytical techniques do not contain zinc or 
phenol, rationally choosing the pH and ionic strength of the technique can give improved 
control as the new derivative is evaluated.  To emphasize the importance of pH control 
many developers (and formulators) define solution phases within ± 0.5 pH units. This 
thesis demonstrates the dramatic importance and sensitivity of the anion exchange pH of 
8.3 versus the pH of 8.8.  I propose that investigators evaluate techniques and 
formulations within ± 0.2 pH units. This concept can be extended to precisely controlling 
pH of reaction chemistries to specifically attach derivatives to reactive groups of insulin 
based on the charge state. 
To evaluate the hexamer equilibrium just before spray drying and to discuss the possible 
mechanism of dissociation, the standard pKa of the amino acids were tabulated in Table 
20, and plotted in Figure 62 (Voet et al 1990).  In the pH range of interest to this 
experiment (6.6 to 8.6), the only ionizable groups are the -amino groups on the 
N-terminals.  The loss of the proton at B1 (50% deprotonated at the pKa value of 8.0) 
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explains the loss of a stabilizing hydrogen bond for the hexamer.  The group has now 
become uncharged or neutral. 
Figure 62: Theoretical charge versus pH. 
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Table 20: Ionizable Amino Acids of Insulin and Approximate Charge State Versus 
pH. 
Pka  pH 13 pH 11 pH 9 pH 7 pH 5 pH 3 pH 2 
12.5 Arg n + + + + + + 
10.8 Lys n n + + + + + 
10.1 Tyr - - n n n n n 
10.1 Tyr - - n n n n n 
10.1 Tyr - - n n n n n 
10.1 Tyr - - n n n n n 
8.0 N-term n n n + + + + 
8.0 N-term n n n + + + + 
6.0 His n n n n + + + 
6.0 His n n n n + + + 
4.3 Glu - - - - - n n 
4.3 Glu - - - - - n n 
4.3 Glu - - - - - n n 
4.3 Glu - - - - - n n 
3.5 C-term - - - - - - n 
3.5 C-term - - - - - - n 
Charge state  -10 -9 -4 -2 0 +4 +6 
 
When incorporated into a protein the approximate pKa’s can shift due to local 
environments, so the exact pKa’s to the tenth decimal are not known. Previous 
investigators have made an assertion that the pKa of the B1 N-terminal -amine group 
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was approximately 7.0 (Baudys et al. 1995). Although their data is suggestive, it is not 
strong enough to confirm the assertion.  This assertion was based on the low reactivity of 
B1 which is sterically hindered and additionally based on the elution pattern from a cation 
exchange column versus the elution pattern on an anion exchange column with no 
description of the cation exchange mobile phase. The positive charges are grouped in 
different density patterns on insulin than the more numerous negative groups.  These 
differences in the charged fields can create very different elution patterns that do not 
require proposing a shift of the pKa of over 1 unit from standard for the N-terminal.  
Finally, Blundell quotes that early workers confirmed the very normal pKa values for the 
-carboxylate and -amino groups for insulin (Blundell et al. 1972).  
Based on the data presented in this thesis in Table 19 all the insulins without zinc 
dissociate the hexamer by about 25% reflected by decreased molecular weight when pH 
is changed from 6.6 to 8.6. The deprotonation of the N- terminus, in the pH range of 7.8 
to 8.5, is an important driving force for the hexamer dissociation.  This strongly suggests 
the pKa of the B1 N-terminal -amine is near the standard range between 7.8 to 8.0. The 
only other charged group in this pH range is the N-terminal A1 -amino, which is not 
involved in the dimer - dimer interface which forms the hexamer.  Certainly the A1 
contributes to overall negative charge and may contribute a repulsive force at some point 
in the assembly. The B1 N-terminal is however directly involved in the hexamer interface 
and if driven to 90% deprotonation at pH 9.0, it supports the theory that the proposed 
hydrogen bonds from B1 to A17 are lost (Blundell et al. 1972, Baker et al. 1988).  B1 is 
surrounded by several other amino acids in the hexamer interface which can also 
contribute stability. Without B1 to additionally stabilize the hexamer at alkaline pH the 
dominant repulsive force formed by the six negatively charged B13 glutamic acids pushes 
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the subunits apart.  When insulin analogs with B13 switched to the neutrally charged 
glutamine were studied, the hexamer formation dramatically increased, which 
demonstrates that B13-glu is the major repulsive force against hexamer formation 
(Hansen et al. 1991). A solution of zinc-free insulin at high concentration and neutral pH 
can overcome this repulsive force as it can form hexamers (Table 19 pH 6.6).   
For the dry powder formulations with low levels of zinc and the B1 amino group 50% 
neutralized at ~ pH 8.0 the like negative charges at B13 appear to interfere substantially 
even at 13.5 mg/mL in the spray dried powder. This is assisted by the low ionic strength 
of the solution before spray drying. The pH is still close enough to neutral in the powders 
to prevent alkaline pH hydrolysis reactions from proceeding. 
Manipulating these parameters has created an insulin powder with remarkable stability.  
Further background data supports the strategy of dissociating the hexamer for improved 
stability. Pre-formulation exercises with Exubera demonstrated that adding additional 
zinc to the formulations reduced the chemical stability slightly (data not shown). This can 
now be related to the high concentration of hexamer in solution before spray drying.  The 
90%, zinc-free, pH 7.8 powder may be capable of 36 months of room temperature 
stability with about 1 to 2% loss in purity. Further optimization may even achieve 
48 months of room temperature stability.  Dissociating the hexamer to even lower levels 
by increasing the pH to 8.0 and lowering the concentration of insulin to 9 mg/mL during 
spray drying would be an obvious next step. 
This leads back to the purpose of understanding the physical and chemical properties that 
are necessary in the preformulation stage.  The PEG insulin with for example a 5000 Da 
PEG already has 50 % excipient or inactive bulking agent diluting the amount of active 
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drug possible in the final form. A very small amount of work was done and some PEG 
insulin powders were spray dried.  The initial powders were formulated at pH 7.3 with 
40% leucine  15% trileucine,  19% sodium citrate, and 26% 750 PEG insulin, which kept 
the PEG at a low 6% of total, and active insulin at 20% by mass. Figure 63 shows the 
extremely  stable spray dried powder, which also had excellent aerosol properties. 
Figure 63: SEM  of 750 Da PEG insulin spray dried leucine formulation, with 
approximately 6% PEG by mass.  
 
 
When a formulation of 15% PEG by mass was spray dried the powder became sticky and 
unstable when put at 50°C stability oven for 12 weeks. This physical instability is not 
even considering the chemical stability. So, formulating the PEG insulins would be a very 
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difficult task if the project were to advance. Pure PEG looks and feels like a wax, so a low 
PEG mass would be a driving force in the formulation process, along with determining 
proper zinc levels. 
Another obvious risk to both regular insulin and PEGylated insulin is fibrillation during 
reconstitution for a spray dried powder made from a solution with extremely high 
monomer concentration (Brange et al. 1997a).  The exposed hydrophobic core of insulin 
monomers is at the heart of this phenomenon, and Brange has stated that a high 
population of the monomeric form is a requirement for this disastrous precipitation event. 
Therefore, careful dissociation of the hexamer with no increase in monomer population 
would be the ideal approach. Also worthy of note was the regular insulin zinc-free 
powders ability to reconstitute identically to Exubera powders in the 1-5 mg/mL range 
with pure water.  This is a very quick dissolution (~30 seconds) with absolutely no 
evidence of fibrils or aggregation, and pH is identical to the pre-spray dried solution. 
This also leads to a question. If a high population of non-covalent dimer is established in 
a solution during spray drying, what new contact surfaces are favored as the water is 
evaporated and the molecules are forced together?  It is likely to be some reconfiguration 
of hydrophobic residues that are involved in the hexamer formation, but are now slightly 
realigned so the B chain is no longer near the A chain, as the covalent dimers no longer 
readily form. Although difficult, this could be studied by any number of techniques to see 
which molecules are in proximity to one another in the dry powder and in the conditions 
right before spray drying.  XRD, FTIR, CD, NMR, and Raman are all techniques that 
have shown utility in describing insulin-insulin interactions (McGraw et al. 1990, Kadima 
et al. 1992, Palmieri, et al. 1988, Pocker et al. 1980).   
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For derivatized or underivatized insulin zinc creates stability by coordinating to the six 
B10 histidine groups which all extend into a central channel through the doughnut shaped 
hexamer. This allows zinc ions free access in an out of the assembly. It is appears that the 
zinc can access the B10 histidine and stabilizes the assembly of all the PEG insulin 
derivatives. What becomes apparent from this study are the N-terminals and the B10 
Histidines are the only charge groups that create the major tension from pH 6 to 9.  As pH 
increases the charge is lost from the N-terminal creating less hexamer stabilization, at the 
same time the Histidines lose the positive charge and strongly bind the zinc stabilizing the 
hexamer.  The N-terminals seem to be the weaker of the two forces because even at 
pH 6.6 where the histidine is closest to its pKa (6.0) the hexamer levels are highest in all 
the insulins, implying that zinc is strongly bound.  It is also expected that the closer the 
pH is to the isoelectric point (equal negative and positive charge) the insulin hexamer will 
be more stable. The importance of the N-terminal charges is additionally supported by the 
DiAc 2000 PEG insulin. Since the N-terminals are neutral by acetylation, it has no change 
in charge state in the range of pH from 6 to 9, and has almost no change in assembly state 
as pH increases, averaging about 1.5, but when zinc is added it dramatically assembles to 
near 4.0. 
It is clear the B29 PEGs are not forming complete hexamers without zinc, and 
unfortunately, the zinc added experiment could not be completed. It is unlikely that the 
hexamer stacking would occur, even with zinc. This is due to the strong hydrophilic 
nature of the PEG.  The fatty acids of Levemir have tendency to interact with the insulin 
while the PEG is just as likely to prefer the bulk solvent.  This freedom of movement will 
prevent stacking. Extrapolating on the B29 zinc-free data it appears the B29 solution with 
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zinc would form a mostly hexameric solution slightly larger than the B1 trend line at 
pH 6.6.  
Assembly data is also available from Ken Hinds who synthesized B1 2000 and B29 
2000 PEG insulin (Hinds et al. 2000).  Hinds used the ultracentrifugation technique in 
50 mM TRIS, pH 7.5, and the samples were at 0.75 mg/mL.  All of the PEG insulins were 
reported to be dimer at those conditions, and the control zinc-insulin was 5.1 average 
assembly state, which is identical to the data in this thesis.   
The conclusion can be drawn that the attached PEG’s main action is sterically hindering 
the normal surfaces of association, and that increasing PEG size increases the 
interference.  The interference is not so dramatic as to cause a high monomeric 
population, and can be assembled using the same pH, zinc, and concentration, techniques 
used to hexamerize regular insulin.  The PEG does not promote the assembly or the 
assembly stability, like fatty acid derivatives do. The PEG is most likely covered with 
associated water and will hydrogen bond briefly with insulin or associate with the bulk 
solvent, thus flapping like a bird wing on the insulin. 
Hinds also reports on fibrillation of the derivatives during a shake study at pH 7.4. While 
the B-29 shows some resistance to fibrillation and withstood 8 days, the B1 derivatives 
were particularly resistant, and withstood a remarkable 20 days of shaking versus 
0.5 days for regular zinc insulin.  Although concentration was not reported by Hinds the 
1mg/mL range is assumed, and B29 2000 may improve its behavior with increased 
concentration to overcome the monomers present, since the B1 2000 should have more 
dimer population as part of its advantage. 
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Further expanding on Hinds discussion of the fibrillation data, as it dovetails well with 
the assembly data presented here. The B1 PEG’s geometry is also sterically interfering 
with the hydrophobic surfaces that lead to hexamer assembly, and this is in agreement 
with Hinds that these are the same surfaces involved in fibrillation with other partially 
unfolded monomers that have been exposed to air or a container surface (Sato et al. 1983, 
Brange et al. 1997a).  Since the nucleation of a fiber requires 4-5 simultaneous monomers 
to start the fibrillation process, the PEG at B1 will easily block the formation of this 
complex interaction.  To explain the B29 fibrillation Figure 64 shows the partially 
unfolded insulin required for fibrillation to occur (Brange et al. 1997a).  If we imagine a 
bulky group such as PEG adding leverage to this pivoting of the extended B21-B30 it can 
explain the midway fibrillation behavior of B29 2000. The competition of an increased 
population of unfolded intermediate, balanced against the PEG at B29 occasionally 
shielding or sterically hindering the exposed core from forming a seed of nucleation, it 
can be seen it would be more prone to fibrillation versus B1 2000, yet improved over 
regular insulin. In addition at lower concentrations the B29 does have a less stable dimer, 
as shown by the SEC-MALS data, and with shaking the monomer population is likely 
higher than B1’s more stable dimer. In other words the B29 has more monomers even 
though it may have some hexamers.  This polydispersity is very difficult to quantitate 
because of the polydispersity of the PEG itself but qualitative comparisons of the 
SEC-MALS shows wider distribution of B29 derivatives from high to low versus B1 
derivatives. This protective function of PEG is a great area for further study. 
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Figure 64: Brange’s proposal of partially unfolded insulin involved in the fibrillation 
process (Brange et al. 1997a). 
 
It would be informative to evaluate the fibrillation data as a function of pH, zinc and even 
phenol, and judge if lower fibrillation would occur with an increase hexamer formation 
between the B29 PEG and B1 PEG insulins.  The ultimate value of low molecular weight 
PEG insulin’s may be to avoid fibrillation in systems like insulin pumps with high shear 
forces. 
The MALS technique has some limitations and areas prone to increased error.  The 
overall error associated with assembly data presented was estimated to be about 4 to 8%. 
This estimate is a combination of insulin concentration error, dn/dc error (due to PEG 
extrapolation), baseline noise due to flow cell contamination, air bubbles, and manual 
peak selection for the calculation software.  The major problem was controlling air 
bubbles in batch mode (infusion by syringe). The 0.02 μm membranes on the syringe 
filters generated considerable air bubbles with the protein solutions. Some solutions were 
prefiltered (to eliminate the in line filter) and allowed to stand in the vial for 2 hours 
before infusion, this proved problematic as the vials were identified later as having oil 
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residue on the interior, which produced very noisy data which was discarded. Carefully 
precleaned vials can be considered with this approach.  Infusion rates were lowered to 
around 0.2 mL/minute to allow the air bubbles to pool in the top of the filter housing and 
not enter the flow cell. Even so, microscopic bubbles required 4-10 minutes to clear the 
lines and flow cell. Higher concentrations of insulin increased the back pressure, which 
then led to increased solution shear forces which precipitated protein and clogged the 
filters. This implies that high shear can disassemble the hexamer. Low back pressure 
should be emphasized. Each experiment may require filter pore size optimization, as 
larger pores will allow the solution to enter, but increases the risk of particles entering the 
flow cell and increasing the noise. The solutions were tried with no filtration and the 
noise was too large. Additional techniques recommended to create the required “clean” 
samples, are vacuum degassing of solutions, and centrifuging to create bubble-free and 
particulate free solutions.  Even, doubly or triply prefiltered samples into ultraclean vials 
should be considered.  Other sources of error may be slight shifts in the assembly 
equilibrium over the course of time and temperature.  It is possible that hexamers may 
take minutes or hours to stabilize or form.  This is a possible experiment for future work.  
A solution could be measured for size at many timepoints based on starting reconstitution 
time. The filtration step was assumed to not distort the association structures because the 
pore size of 20 nm is 4 times the size of a 5 nm hexamer, and the flow rate was kept very 
low, but this also needs to be verified.  
This thesis highlights how insulin continues to lead the way as a therapeutic agent and as 
a model for developing technology. 
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